1
|
Kistler LM, Asamura K, Kasahara S, Miyoshi Y, Mouikis CG, Keika K, Petrinec SM, Stevens ML, Hori T, Yokota S, Shinohara I. The variable source of the plasma sheet during a geomagnetic storm. Nat Commun 2023; 14:6143. [PMID: 37903790 PMCID: PMC10616164 DOI: 10.1038/s41467-023-41735-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2023] [Accepted: 09/12/2023] [Indexed: 11/01/2023] Open
Abstract
Both solar wind and ionospheric sources contribute to the magnetotail plasma sheet, but how their contribution changes during a geomagnetic storm is an open question. The source is critical because the plasma sheet properties control the enhancement and decay rate of the ring current, the main cause of the geomagnetic field perturbations that define a geomagnetic storm. Here we use the solar wind composition to track the source and show that the plasma sheet source changes from predominantly solar wind to predominantly ionospheric as a storm develops. Additionally, we find that the ionospheric plasma during the storm main phase is initially dominated by singly ionized hydrogen (H+), likely from the polar wind, a low energy outflow from the polar cap, and then transitions to the accelerated outflow from the dayside and nightside auroral regions, identified by singly ionized oxygen (O+). These results reveal how the access to the magnetotail of the different sources can change quickly, impacting the storm development.
Collapse
Affiliation(s)
- L M Kistler
- University of New Hampshire, Durham, NH, USA.
- Nagoya University, Nagoya, Japan.
| | - K Asamura
- Japan Aerospace Exploration Agency, Sagamihara, Japan
| | | | | | - C G Mouikis
- University of New Hampshire, Durham, NH, USA
| | - K Keika
- University of Tokyo, Tokyo, Japan
| | - S M Petrinec
- Lockheed Martin Advanced Technology Center, Palo Alto, CA, USA
| | - M L Stevens
- Harvard-Smithsonian Center for Astrophysics, Cambridge, MA, USA
| | - T Hori
- Nagoya University, Nagoya, Japan
| | - S Yokota
- Osaka University, Toyonaka, Japan
| | - I Shinohara
- Japan Aerospace Exploration Agency, Sagamihara, Japan
| |
Collapse
|
2
|
Fujita N, Ono Y, Kobayashi T, Kozono S, Horiuchi Y, Sano A, Kawamura Y, Miyoshi Y, Kimata M, Sekizawa A, Hashimoto K, Obuchi Y, Tanaka Y. Iodine-containing ointment-induced hypothyroidism in a patient with anorexia nervosa and sacral decubitus ulcer: a case report with literature review. Endocr J 2022; 69:1423-1429. [PMID: 36058848 DOI: 10.1507/endocrj.ej22-0248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
We present a case of a 58-year-old woman with anorexia nervosa and a sacral decubitus ulcer who developed hypothyroidism because of an iodine-containing ointment. Considering the absence of autoimmune thyroid diseases, the development of hypothyroidism after the use of an iodine-containing ointment, and the recovery of thyroid function after the discontinuation of the ointment, we presumed that her hypothyroidism was induced by the iodine-containing ointment. Although the hypothyroidism improved after discontinuing the iodine-containing ointment, she developed aspiration pneumonia and required long-term hospitalization. Many patients with autoimmune thyroid diseases develop hypothyroidism after excessive iodine intake. However, anorexia nervosa may have exacerbated the iodine-induced hypothyroidism in our patient. To the best of our knowledge, no previous study has reported a case of hypothyroidism caused by iodine-containing ointment in a patient with anorexia nervosa. Hence, physicians must pay careful attention to a patient's background factors to ensure the early diagnosis of hypothyroidism due to iodine-containing ointments.
Collapse
Affiliation(s)
- Naoya Fujita
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| | - Yosuke Ono
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| | - Takahiro Kobayashi
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| | - Sawako Kozono
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| | - Yugo Horiuchi
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| | - Azusa Sano
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| | - Yusuke Kawamura
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| | - Yuka Miyoshi
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| | - Motohiro Kimata
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| | - Akinori Sekizawa
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| | - Kenichi Hashimoto
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| | - Yasuhiro Obuchi
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| | - Yuji Tanaka
- Department of General Medicine, National Defense Medical College, Saitama 359-8513, Japan
| |
Collapse
|
3
|
Nadarajah R, Ludman P, Appelman Y, Brugaletta S, Budaj A, Bueno H, Huber K, Kunadian V, Leonardi S, Lettino M, Milasinovic D, Gale CP, Budaj A, Dagres N, Danchin N, Delgado V, Emberson J, Friberg O, Gale CP, Heyndrickx G, Iung B, James S, Kappetein AP, Maggioni AP, Maniadakis N, Nagy KV, Parati G, Petronio AS, Pietila M, Prescott E, Ruschitzka F, Van de Werf F, Weidinger F, Zeymer U, Gale CP, Beleslin B, Budaj A, Chioncel O, Dagres N, Danchin N, Emberson J, Erlinge D, Glikson M, Gray A, Kayikcioglu M, Maggioni AP, Nagy KV, Nedoshivin A, Petronio AP, Roos-Hesselink JW, Wallentin L, Zeymer U, Popescu BA, Adlam D, Caforio ALP, Capodanno D, Dweck M, Erlinge D, Glikson M, Hausleiter J, Iung B, Kayikcioglu M, Ludman P, Lund L, Maggioni AP, Matskeplishvili S, Meder B, Nagy KV, Nedoshivin A, Neglia D, Pasquet AA, Roos-Hesselink JW, Rossello FJ, Shaheen SM, Torbica A, Gale CP, Ludman PF, Lettino M, Bueno H, Huber K, Leonardi S, Budaj A, Milasinovic (Serbia) D, Brugaletta S, Appelman Y, Kunadian V, Al Mahmeed WAR, Kzhdryan H, Dumont C, Geppert A, Bajramovic NS, Cader FA, Beauloye C, Quesada D, Hlinomaz O, Liebetrau C, Marandi T, Shokry K, Bueno H, Kovacevic M, Crnomarkovic B, Cankovic M, Dabovic D, Jarakovic M, Pantic T, Trajkovic M, Pupic L, Ruzicic D, Cvetanovic D, Mansourati J, Obradovic I, Stankovic M, Loh PH, Kong W, Poh KK, Sia CH, Saw K, Liška D, Brozmannová D, Gbur M, Gale CP, Maxian R, Kovacic D, Poznic NG, Keric T, Kotnik G, Cercek M, Steblovnik K, Sustersic M, Cercek AC, Djokic I, Maisuradze D, Drnovsek B, Lipar L, Mocilnik M, Pleskovic A, Lainscak M, Crncic D, Nikojajevic I, Tibaut M, Cigut M, Leskovar B, Sinanis T, Furlan T, Grilj V, Rezun M, Mateo VM, Anguita MJF, Bustinza ICM, Quintana RB, Cimadevilla OCF, Fuertes J, Lopez F, Dharma S, Martin MD, Martinez L, Barrabes JA, Bañeras J, Belahnech Y, Ferreira-Gonzalez I, Jordan P, Lidon RM, Mila L, Sambola A, Orvin K, Sionis A, Bragagnini W, Cambra AD, Simon C, Burdeus MV, Ariza-Solé A, Alegre O, Alsina M, Ferrando JIL, Bosch X, Sinha A, Vidal P, Izquierdo M, Marin F, Esteve-Pastor MA, Tello-Montoliu A, Lopez-Garcia C, Rivera-Caravaca JM, Gil-Pérez P, Nicolas-Franco S, Keituqwa I, Farhan HA, Silva L, Blasco A, Escudier JM, Ortega J, Zamorano JL, Sanmartin M, Pereda DC, Rincon LM, Gonzalez P, Casado T, Sadeghipour P, Lopez-Sendon JL, Manjavacas AMI, Marin LAM, Sotelo LR, Rodriguez SOR, Bueno H, Martin R, Maruri R, Moreno G, Moris C, Gudmundsdottir I, Avanzas P, Ayesta A, Junco-Vicente A, Cubero-Gallego H, Pascual I, Sola NB, Rodriguez OA, Malagon L, Martinez-Basterra J, Arizcuren AM, Indolfi C, Romero J, Calleja AG, Fuertes DG, Crespín Crespín M, Bernal FJC, Ojeda FB, Padron AL, Cabeza MM, Vargas CM, Yanes G, Kitai T, Gonzalez MJG, Gonzalez Gonzalez J, Jorge P, De La Fuente B, Bermúdez MG, Perez-Lopez CMB, Basiero AB, Ruiz AC, Pamias RF, Chamero PS, Mirrakhimov E, Hidalgo-Urbano R, Garcia-Rubira JC, Seoane-Garcia T, Arroyo-Monino DF, Ruiz AB, Sanz-Girgas E, Bonet G, Rodríguez-López J, Scardino C, De Sousa D, Gustiene O, Elbasheer E, Humida A, Mahmoud H, Mohamed A, Hamid E, Hussein S, Abdelhameed M, Ali T, Ali Y, Eltayeb M, Philippe F, Ali M, Almubarak E, Badri M, Altaher S, Alla MD, Dellborg M, Dellborg H, Hultsberg-Olsson G, Marjeh YB, Abdin A, Erglis A, Alhussein F, Mgazeel F, Hammami R, Abid L, Bahloul A, Charfeddine S, Ellouze T, Canpolat U, Oksul M, Muderrisoglu H, Popovici M, Karacaglar E, Akgun A, Ari H, Ari S, Can V, Tuncay B, Kaya H, Dursun L, Kalenderoglu K, Tasar O, Kalpak O, Kilic S, Kucukosmanoglu M, Aytekin V, Baydar O, Demirci Y, Gürsoy E, Kilic A, Yildiz Ö, Arat-Ozkan A, Sinan UY, Dagva M, Gungor B, Sekerci SS, Zeren G, Erturk M, Demir AR, Yildirim C, Can C, Kayikcioglu M, Yagmur B, Oney S, Xuereb RG, Sabanoglu C, Inanc IH, Ziyrek M, Sen T, Astarcioglu MA, Kahraman F, Utku O, Celik A, Surmeli AO, Basaran O, Ahmad WAW, Demirbag R, Besli F, Gungoren F, Ingabire P, Mondo C, Ssemanda S, Semu T, Mulla AA, Atos JS, Wajid I, Appelman Y, Al Mahmeed WAR, Atallah B, Bakr K, Garrod R, Makia F, Eldeeb F, Abdekader R, Gomaa A, Kandasamy S, Maruthanayagam R, Nadar SK, Nakad G, Nair R, Mota P, Prior P, Mcdonald S, Rand J, Schumacher N, Abraheem A, Clark M, Coulding M, Qamar N, Turner V, Negahban AQ, Crew A, Hope S, Howson J, Jones S, Lancaster N, Nicholson A, Wray G, Donnelly P, Gierlotka M, Hammond L, Hammond S, Regan S, Watkin R, Papadopoulos C, Ludman P, Hutton K, Macdonald S, Nilsson A, Roberts S, Monteiro S, Garg S, Balachandran K, Mcdonald J, Singh R, Marsden K, Davies K, Desai H, Goddard W, Iqbal N, Chalil S, Dan GA, Galasko G, Assaf O, Benham L, Brown J, Collins S, Fleming C, Glen J, Mitchell M, Preston S, Uttley A, Radovanovic M, Lindsay S, Akhtar N, Atkinson C, Vinod M, Wilson A, Clifford P, Firoozan S, Yashoman M, Bowers N, Chaplin J, Reznik EV, Harvey S, Kononen M, Lopesdesousa G, Saraiva F, Sharma S, Cruddas E, Law J, Young E, Hoye A, Harper P, Balghith M, Rowe K, Been M, Cummins H, French E, Gibson C, Abraham JA, Hobson S, Kay A, Kent M, Wilkinson A, Mohamed A, Clark S, Duncan L, Ahmed IM, Khatiwada D, Mccarrick A, Wanda I, Read P, Afsar A, Rivers V, Theobald T, Cercek M, Bell S, Buckman C, Francis R, Peters G, Stables R, Morgan M, Noorzadeh M, Taylor B, Twiss S, Widdows P, Brozmannová D, Wilkinson V, Black M, Clark A, Clarkson N, Currie J, George L, Mcgee C, Izzat L, Lewis T, Omar Z, Aytekin V, Phillips S, Ahmed F, Mackie S, Oommen A, Phillips H, Sherwood M, Aleti S, Charles T, Jose M, Kolakaluri L, Ingabire P, Karoudi RA, Deery J, Hazelton T, Knight A, Price C, Turney S, Kardos A, Williams F, Wren L, Bega G, Alyavi B, Scaletta D, Kunadian V, Cullen K, Jones S, Kirkup E, Ripley DP, Matthews IG, Mcleod A, Runnett C, Thomas HE, Cartasegna L, Gunarathne A, Burton J, King R, Quinn J, Sobolewska J, Munt S, Porter J, Christenssen V, Leng K, Peachey T, Gomez VN, Temple N, Wells K, Viswanathan G, Taneja A, Cann E, Eglinton C, Hyams B, Jones E, Reed F, Smith J, Beltrano C, Affleck DC, Turner A, Ward T, Wilmshurst N, Stirrup J, Brunton M, Whyte A, Smith S, Murray V, Walker R, Novas V, Weston C, Brown C, Collier D, Curtis K, Dixon K, Wells T, Trim F, Ghosh J, Mavuri M, Barman L, Dumont C, Elliott K, Harrison R, Mallinson J, Neale T, Smith J, Toohie J, Turnbull A, Parker E, Hossain R, Cheeseman M, Balparda H, Hill J, Hood M, Hutchinson D, Mellows K, Pendlebury C, Storey RF, Barker J, Birchall K, Denney H, Housley K, Cardona M, Middle J, Kukreja N, Gati S, Kirk P, Lynch M, Srinivasan M, Szygula J, Baker P, Cruz C, Derigay J, Cigalini C, Lamb K, Nembhard S, Price A, Mamas M, Massey I, Wain J, Delaney J, Junejo S, Martin K, Obaid D, Hoyle V, Brinkworth E, Davies C, Evans D, Richards S, Thomas C, Williams M, Dayer M, Mills H, Roberts K, Goodchild F, Dámaso ES, Greig N, Kundu S, Donaldson D, Tonks L, Beekes M, Button H, Hurford F, Motherwell N, Summers-Wall J, Felmeden D, Tapia V, Keeling P, Sheikh U, Yonis A, Felmeden L, Hughes D, Micklewright L, Summerhayes A, Sutton J, Panoulas V, Prendergast C, Poghosyan K, Rogers P, Barker LN, Batin P, Conway D, Exley D, Fletcher A, Wright J, Nageh T, Hadebe B, Kunhunny S, Mkhitaryan S, Mshengu E, Karthikeyan VJ, Hamdan H, Cooper J, Dandy C, Parkinson V, Paterson P, Reddington S, Taylor T, Tierney C, Adamyan M, Jones KV, Broadley A, Beesley K, Buckley C, Hellyer C, Pippard L, Pitt-Kerby T, Azam J, Hayes C, Freshwater K, Boyadjian S, Johnson L, Mcgill Y, Redfearn H, Russell M, Alyavi A, Alyavi B, Uzokov J, Hayrapetyan H, Azaryan K, Tadevosyan M, Poghosyan H, Kzhdryan H, Vardanyan A, Huber K, Geppert A, Ahmed A, Weidinger F, Derntl M, Hasun M, Schuh-Eiring T, Riegler L, Haq MM, Cader FA, Dewan MAM, Fatema ME, Hasan AS, Islam MM, Khandoker F, Mayedah R, Nizam SU, Azam MG, Arefin MM, Jahan J, Schelfaut D, De Raedt H, Wouters S, Aerts S, Batjoens H, Beauloye C, Dechamps M, Pierard S, Van Caenegem O, Sinnaeve F, Claeys MJ, Snepvangers M, Somers V, Gevaert S, Schaubroek H, Vervaet P, Buysse M, Renders F, Dumoulein M, Hiltrop N, De Coninck M, Naessens S, Senesael I, Hoffer E, Pourbaix S, Beckers J, Dugauquier C, Jacquet S, Malmendier D, Massoz M, Evrard P, Collard L, Brunner P, Carlier S, Blockmans M, Mayne D, Timiras E, Guédès A, Demeure F, Hanet C, Domange J, Jourdan K, Begic E, Custovic F, Dozic A, Hrvat E, Kurbasic I, Mackic D, Subo A, Durak-Nalbantic A, Dzubur A, Rebic D, Hamzic-Mehmedbasic A, Redzepovic A, Djokic-Vejzovic A, Hodzic E, Hujdur M, Musija E, Gljiva-Gogic Z, Serdarevic N, Bajramovic NS, Brigic L, Halilcevic M, Cibo M, Hadžibegic N, Kukavica N, Begic A, Iglica A, Osmanagic A, Resic N, Grgurevic MV, Zvizdic F, Pojskic B, Mujaric E, Selimovic H, Ejubovic M, Pojskic L, Stimjanin E, Sut M, Zapata PS, Munoz CG, Andrade LAF, Upegui MPT, Perez LE, Chavarria J, Quesada D, Alvarado K, Zaputovic L, Tomulic V, Gobic D, Jakljevic T, Lulic D, Bacic G, Bastiancic L, Avraamides P, Eftychiou C, Eteocleous N, Ioannou A, Lambrianidi C, Drakomathioulakis M, Groch L, Hlinomaz O, Rezek M, Semenka J, Sitar J, Beranova M, Kramarikova P, Pesl L, Sindelarova S, Tousek F, Warda HM, Ghaly I, Habiba S, Habib A, Gergis MN, Bahaa H, Samir A, Taha HSE, Adel M, Algamal HM, Mamdouh M, Shaker AF, Shokry K, Konsoah A, Mostafa AM, Ibrahim A, Imam A, Hafez B, Zahran A, Abdelhamid M, Mahmoud K, Mostafa A, Samir A, Abdrabou M, Kamal A, Sallam S, Ali A, Maghraby K, Atta AR, Saad A, Ali M, Lotman EM, Lubi R, Kaljumäe H, Uuetoa T, Kiitam U, Durier C, Ressencourt O, El Din AA, Guiatni A, Bras ML, Mougenot E, Labeque JN, Banos JL, Capendeguy O, Mansourati J, Fofana A, Augagneur M, Bahon L, Pape AL, Batias-Moreau L, Fluttaz A, Good F, Prieur F, Boiffard E, Derien AS, Drapeau I, Roy N, Perret T, Dubreuil O, Ranc S, Rio S, Bonnet JL, Bonnet G, Cuisset T, Deharo P, Mouret JP, Spychaj JC, Blondelon A, Delarche N, Decalf V, Guillard N, Hakme A, Roger MP, Biron Y, Druelles P, Loubeyre C, Lucon A, Hery P, Nejjari M, Digne F, Huchet F, Neykova A, Tzvetkov B, Larrieu M, Quaino G, Armangau P, Sauguet A, Bonfils L, Dumonteil N, Fajadet J, Farah B, Honton B, Monteil B, Philippart R, Tchetche D, Cottin M, Petit F, Piquart A, Popovic B, Varlot J, Maisuradze D, Sagirashvili E, Kereselidze Z, Totladze L, Ginturi T, Lagvilava D, Hamm C, Liebetrau C, Haas M, Hamm C, Koerschgen T, Weferling M, Wolter JS, Maier K, Nickenig G, Sedaghat A, Zachoval C, Lampropoulos K, Mpatsouli A, Sakellaropoulou A, Tyrovolas K, Zibounoumi N, Argyropoulos K, Toulgaridis F, Kolyviras A, Tzanis G, Tzifos V, Milkas A, Papaioannou S, Kyriazopoulos K, Pylarinou V, Kontonassakis I, Kotakos C, Kourgiannidis G, Ntoliou P, Parzakonis N, Pipertzi A, Sakalidis A, Ververeli CL, Kafkala K, Sinanis T, Diakakis G, Grammatikopoulos K, Papoutsaki E, Patialiatos T, Mamaloukaki M, Papadaki ST, Kanellos IE, Antoniou A, Tsinopoulos G, Goudis C, Giannadaki M, Daios S, Petridou M, Skantzis P, Koukis P, Dimitriadis F, Savvidis M, Styliadis I, Sachpekidis V, Pilalidou A, Stamatiadis N, Fotoglidis A, Karakanas A, Ruzsa Z, Becker D, Nowotta F, Gudmundsdottir I, Libungan B, Skuladottir FB, Halldorsdottir H, Shetty R, Iyengar S, Bs C, G S, Lakshmana S, S R, Tripathy N, Sinha A, Choudhary B, Kumar A, Kumar A, Raj R, Roy RS, Dharma S, Siswanto BB, Farhan HA, Yaseen IF, Al-Zaidi M, Dakhil Z, Amen S, Rasool B, Rajeeb A, Amber K, Ali HH, Al-Kinani T, Almyahi MH, Al-Obaidi F, Masoumi G, Sadeghi M, Heshmat-Ghahdarijani K, Roohafza H, Sarrafzadegan N, Shafeie M, Teimouri-Jervekani Z, Noori F, Kyavar M, Sadeghipour P, Firouzi A, Alemzadeh-Ansari MJ, Ghadrdoost B, Golpira R, Ghorbani A, Ahangari F, Salarifar M, Jenab Y, Biria A, Haghighi S, Mansouri P, Yadangi S, Kornowski R, Orvin K, Eisen A, Oginetz N, Vizel R, Kfir H, Pasquale GD, Casella G, Cardelli LS, Filippini E, Zagnoni S, Donazzan L, Ermacora D, Indolfi C, Polimeni A, Curcio A, Mongiardo A, De Rosa S, Sorrentino S, Spaccarotella C, Landolina M, Marino M, Cacucci M, Vailati L, Bernabò P, Montisci R, Meloni L, Marchetti MF, Biddau M, Garau E, Barbato E, Morisco C, Strisciuglio T, Canciello G, Lorenzoni G, Casu G, Merella P, Novo G, D'Agostino A, Di Lisi D, Di Palermo A, Evola S, Immordino F, Rossetto L, Spica G, Pavan D, Mattia AD, Belfiore R, Grandis U, Vendrametto F, Spagnolo C, Carniel L, Sonego E, Gaudio C, Barillà F, Biccire FG, Bruno N, Ferrari I, Paravati V, Torromeo C, Galasso G, Peluso A, Prota C, Radano I, Benvenga RM, Ferraioli D, Anselmi M, Frigo GM, Sinagra G, Merlo M, Perkan A, Ramani F, Altinier A, Fabris E, Rinaldi M, Usmiani T, Checco L, Frea S, Mussida M, Matsukawa R, Sugi K, Kitai T, Furukawa Y, Masumoto A, Miyoshi Y, Nishino S, Assembekov B, Amirov B, Chernokurova Y, Ibragimova F, Mirrakhimov E, Ibraimova A, Murataliev T, Radzhapova Z, Uulu ES, Zhanyshbekova N, Zventsova V, Erglis A, Bondare L, Zaliunas R, Gustiene O, Dirsiene R, Marcinkeviciene J, Sakalyte G, Virbickiene A, Baksyte G, Bardauskiene L, Gelmaniene R, Salkauskaite A, Ziubryte G, Kupstyte-Kristapone N, Badariene J, Balciute S, Kapleriene L, Lizaitis M, Marinskiene J, Navickaite A, Pilkiene A, Ramanauskaite D, Serpytis R, Silinskiene D, Simbelyte T, Staigyte J, Philippe F, Degrell P, Camus E, Ahmad WAW, Kassim ZA, Xuereb RG, Buttigieg LL, Camilleri W, Pllaha E, Xuereb S, Popovici M, Ivanov V, Plugaru A, Moscalu V, Popovici I, Abras M, Ciobanu L, Litvinenco N, Fuior S, Dumanschi C, Ivanov M, Danila T, Grib L, Filimon S, Cardaniuc L, Batrinac A, Tasnic M, Cozma C, Revenco V, Sorici G, Dagva M, Choijiljav G, Dandar E, Khurelbaatar MU, Tsognemekh B, Appelman Y, Den Hartog A, Kolste HJT, Van Den Buijs D, Van'T Hof A, Pustjens T, Houben V, Kasperski I, Ten Berg J, Azzahhafi J, Bor W, Yin DCP, Mbakwem A, Amadi C, Kushimo O, Kilasho M, Oronsaye E, Bakracheski N, Bashuroska EK, Mojsovska V, Tupare S, Dejan M, Jovanoska J, Razmoski D, Marinoski T, Antovski A, Jovanovski Z, Kocho S, Markovski R, Ristovski V, Samir AB, Biserka S, Kalpak O, Peovska IM, Taleska BZ, Pejkov H, Busljetik O, Zimbakov Z, Grueva E, Bojovski I, Tutic M, Poposka L, Vavlukis M, Al-Riyami A, Nadar SK, Abdelmottaleb W, Ahmed S, Mujtaba MS, Al-Mashari S, Al-Riyami H, Laghari AH, Faheem O, Ahmed SW, Qamar N, Furnaz S, Kazmi K, Saghir T, Aneel A, Asim A, Madiha F, Sobkowicz B, Tycinska A, Kazimierczyk E, Szyszkowska A, Mizia-Stec K, Wybraniec M, Bednarek A, Glowacki K, Prokopczuk J, Babinski W, Blachut A, Kosiak M, Kusinska A, Samborski S, Stachura J, Szastok H, Wester A, Bartoszewska D, Sosnowska-Pasiarska B, Krzysiek M, Legutko J, Nawrotek B, Kasprzak JD, Klosinska M, Wiklo K, Kurpesa M, Rechcinski T, Cieslik-Guerra U, Gierlotka M, Bugajski J, Feusette P, Sacha J, Przybylo P, Krzesinski P, Ryczek R, Karasek A, Kazmierczak-Dziuk A, Mielniczuk M, Betkier-Lipinska K, Roik M, Labyk A, Krakowian M, Machowski M, Paczynska M, Potepa M, Pruszczyk P, Budaj A, Ambroziak M, Omelanczuk-Wiech E, Torun A, Opolski G, Glowczynska R, Fojt A, Kowalik R, Huczek Z, Jedrzejczyk S, Roleder T, Brust K, Gasior M, Desperak P, Hawranek M, Farto-Abreu P, Santos M, Baptista S, Brizida L, Faria D, Loureiro J, Magno P, Monteiro C, Nédio M, Tavares J, Sousa C, Almeida I, Almeida S, Miranda H, Santos H, Santos AP, Goncalves L, Monteiro S, Baptista R, Ferreira C, Ferreira J, Goncalves F, Lourenço C, Monteiro P, Picarra B, Santos AR, Guerreiro RA, Carias M, Carrington M, Pais J, de Figueiredo MP, Rocha AR, Mimoso J, De Jesus I, Fernandes R, Guedes J, Mota T, Mendes M, Ferreira J, Tralhão A, Aguiar CT, Strong C, Da Gama FF, Pais G, Timóteo AT, Rosa SAO, Mano T, Reis J, Selas M, Mendes DE, Satendra M, Pinto P, Queirós C, Oliveira I, Reis L, Cruz I, Fernandes R, Torres S, Luz A, Campinas A, Costa R, Frias A, Oliveira M, Martins V, Castilho B, Coelho C, Moura AR, Cotrim N, Dos Santos RC, Custodio P, Duarte R, Gomes R, Matias F, Mendonca C, Neiva J, Rabacal C, Almeida AR, Caeiro D, Queiroz P, Silva G, Pop-Moldovan AL, Darabantiu D, Mercea S, Dan GA, Dan AR, Dobranici M, Popescu RA, Adam C, Sinescu CJ, Andrei CL, Brezeanu R, Samoila N, Baluta MM, Pop D, Tomoaia R, Istratoaie O, Donoiu I, Cojocaru A, Oprita OC, Rocsoreanu A, Grecu M, Ailoaei S, Popescu MI, Cozma A, Babes EE, Rus M, Ardelean A, Larisa R, Moisi M, Ban E, Buzle A, Filimon G, Dobreanu D, Lupu S, Mitre A, Rudzik R, Sus I, Opris D, Somkereki C, Mornos C, Petrescu L, Betiu A, Volcescu A, Ioan O, Luca C, Maximov D, Mosteoru S, Pascalau L, Roman C, Brie D, Crisan S, Erimescu C, Falnita L, Gaita D, Gheorghiu M, Levashov S, Redkina M, Novitskii N, Dementiev E, Baglikov A, Zateyshchikov D, Zubova E, Rogozhina A, Salikov A, Nikitin I, Reznik EV, Komissarova MS, Shebzukhova M, Shitaya K, Stolbova S, Larina V, Akhmatova F, Chuvarayan G, Arefyev MN, Averkov OV, Volkova AL, Sepkhanyan MS, Vecherko VI, Meray I, Babaeva L, Goreva L, Pisaryuk A, Potapov P, Teterina M, Ageev F, Silvestrova G, Fedulaev Y, Pinchuk T, Staroverov I, Kalimullin D, Sukhinina T, Zhukova N, Ryabov V, Kruchinkina E, Vorobeva D, Shevchenko I, Budyak V, Elistratova O, Fetisova E, Islamov R, Ponomareva E, Khalaf H, Shaimaa AA, Kamal W, Alrahimi J, Elshiekh A, Balghith M, Ahmed A, Attia N, Jamiel AA, Potpara T, Marinkovic M, Mihajlovic M, Mujovic N, Kocijancic A, Mijatovic Z, Radovanovic M, Matic D, Milosevic A, Savic L, Subotic I, Uscumlic A, Zlatic N, Antonijevic J, Vesic O, Vucic R, Martinovic SS, Kostic T, Atanaskovic V, Mitic V, Stanojevic D, Petrovic M. Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry. Eur Heart J Qual Care Clin Outcomes 2022; 9:8-15. [PMID: 36259751 DOI: 10.1093/ehjqcco/qcac067] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Accepted: 10/11/2022] [Indexed: 11/12/2022]
Abstract
AIMS The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. METHODS AND RESULTS Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics, major outcomes (in-hospital death, acute heart failure, cardiogenic shock, bleeding, stroke/transient ischaemic attack, and 30-day mortality) and guideline-recommended NSTEMI care interventions: electrocardiogram pre- or in-hospital, pre-hospitalization receipt of aspirin, echocardiography, coronary angiography, referral to cardiac rehabilitation, smoking cessation advice, dietary advice, and prescription on discharge of aspirin, P2Y12 inhibition, angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta-blocker, and statin. CONCLUSION The EORP NSTEMI Registry is an international, prospective registry of care and outcomes of patients treated for NSTEMI, which will provide unique insights into the contemporary management of hospitalised NSTEMI patients, compliance with ESC 2015 NSTEMI Guidelines, and identify potential barriers to optimal management of this common clinical presentation associated with significant morbidity and mortality.
Collapse
Affiliation(s)
- Ramesh Nadarajah
- Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK.,Leeds Institute of Data Analytics, University of Leeds, LS2 9JT Leeds, UK.,Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK
| | - Peter Ludman
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| | - Yolande Appelman
- Department of Cardiology, Amsterdam UMC-Vrije Universiteit, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands
| | - Salvatore Brugaletta
- Hospital Clinic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Andrzej Budaj
- Department of Cardiology, Center of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland
| | - Hector Bueno
- Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.,Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.,Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
| | - Kurt Huber
- 3rd Medical Department, Cardiology and Intensive Care Medicine, Clinic Ottakring (Wilhelminenhospital), Vienna, Austria.,Medical Faculty, Sigmund Freud University, Vienna, Austria
| | - Vijay Kunadian
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.,Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
| | - Sergio Leonardi
- University of Pavia, Pavia, Italy.,Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy
| | - Maddalena Lettino
- Cardio-Thoracic and Vascular Department, San Gerardo Hospital, ASST-Monza, Monza, Italy
| | - Dejan Milasinovic
- Department of Cardiology, University Clinical Center of Serbia and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - Chris P Gale
- Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK.,Leeds Institute of Data Analytics, University of Leeds, LS2 9JT Leeds, UK.,Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Kitamura N, Amano T, Omura Y, Boardsen SA, Gershman DJ, Miyoshi Y, Kitahara M, Katoh Y, Kojima H, Nakamura S, Shoji M, Saito Y, Yokota S, Giles BL, Paterson WR, Pollock CJ, Barrie AC, Skeberdis DG, Kreisler S, Le Contel O, Russell CT, Strangeway RJ, Lindqvist PA, Ergun RE, Torbert RB, Burch JL. Direct observations of energy transfer from resonant electrons to whistler-mode waves in magnetosheath of Earth. Nat Commun 2022; 13:6259. [PMID: 36307443 PMCID: PMC9616889 DOI: 10.1038/s41467-022-33604-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Accepted: 09/22/2022] [Indexed: 11/30/2022] Open
Abstract
Electromagnetic whistler-mode waves in space plasmas play critical roles in collisionless energy transfer between the electrons and the electromagnetic field. Although resonant interactions have been considered as the likely generation process of the waves, observational identification has been extremely difficult due to the short time scale of resonant electron dynamics. Here we show strong nongyrotropy, which rotate with the wave, of cyclotron resonant electrons as direct evidence for the locally ongoing secular energy transfer from the resonant electrons to the whistler-mode waves using ultra-high temporal resolution data obtained by NASA’s Magnetospheric Multiscale (MMS) mission in the magnetosheath. The nongyrotropic electrons carry a resonant current, which is the energy source of the wave as predicted by the nonlinear wave growth theory. This result proves the nonlinear wave growth theory, and furthermore demonstrates that the degree of nongyrotropy, which cannot be predicted even by that nonlinear theory, can be studied by observations. Excitation of whistler-mode waves by cyclotron instability is considered as the likely generation process of the waves. Here, the authors show direct observational evidence for locally ongoing secular energy transfer from the resonant electrons to the whistler-mode waves in Earth’s magnetosheath.
Collapse
Affiliation(s)
- N Kitamura
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan. .,Department of Earth and Planetary Science, Graduate School of Science, the University of Tokyo, Tokyo, Japan.
| | - T Amano
- Department of Earth and Planetary Science, Graduate School of Science, the University of Tokyo, Tokyo, Japan
| | - Y Omura
- Research Institute for Sustainable Humanosphere, Kyoto University, Uji, Japan
| | - S A Boardsen
- NASA Goddard Space Flight Center, Greenbelt, MD, USA.,Goddard Planetary Heliophysics Institute, University of Maryland, Baltimore County, MD, USA
| | - D J Gershman
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - Y Miyoshi
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - M Kitahara
- Department of Geophysics, Graduate school of Science, Tohoku University, Sendai, Japan
| | - Y Katoh
- Department of Geophysics, Graduate school of Science, Tohoku University, Sendai, Japan
| | - H Kojima
- Research Institute for Sustainable Humanosphere, Kyoto University, Uji, Japan
| | - S Nakamura
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - M Shoji
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - Y Saito
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, Japan
| | - S Yokota
- Department of Earth and Space Science, Graduate School of Science, Osaka University, Toyonaka, Japan
| | - B L Giles
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - W R Paterson
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | | | - A C Barrie
- NASA Goddard Space Flight Center, Greenbelt, MD, USA.,Aurora Engineering, Potomac, MD, USA
| | - D G Skeberdis
- NASA Goddard Space Flight Center, Greenbelt, MD, USA.,a.i. solutions Inc, Lanham, MD, USA
| | - S Kreisler
- NASA Goddard Space Flight Center, Greenbelt, MD, USA.,Aurora Engineering, Potomac, MD, USA
| | - O Le Contel
- Laboratoire de Physique des Plasmas, CNRS/Sorbonne Université/Université Paris-Saclay/Observatoire de Paris/Ecole Polytechnique Institut Polytechnique de Paris, Paris, France
| | - C T Russell
- Department of Earth, Planetary, and Space Science, University of California, Los Angeles, CA, USA
| | - R J Strangeway
- Department of Earth, Planetary, and Space Science, University of California, Los Angeles, CA, USA
| | | | - R E Ergun
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO, USA
| | - R B Torbert
- Department of Physics, University of New Hampshire, Durham, NH, USA.,Southwest Research Institute, San Antonio, TX, USA
| | - J L Burch
- Southwest Research Institute, San Antonio, TX, USA
| |
Collapse
|
5
|
Nakamoto S, Taira N, Kawada K, Takabatake D, Miyoshi Y, Kubo S, Suzuki Y, Yamamoto M, Ogasawara Y, Yoshitomi S, Hara K, Shien T, Iwamoto T, Ohsumi S, Ikeda M, Mizota Y, Yamamoto S, Doihara H. 176P The effectiveness of long-term physical activity after exercise and educational programs on breast cancer-related lymphoedema: Secondary analyses from a randomized controlled trial: The Setouchi Breast Project 10. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
6
|
Elliott SS, Breneman AW, Colpitts C, Pettit JM, Cattell CA, Halford AJ, Shumko M, Sample J, Johnson AT, Miyoshi Y, Kasahara Y, Cully CM, Nakamura S, Mitani T, Hori T, Shinohara I, Shiokawa K, Matsuda S, Connors M, Ozaki M, Manninen J. Quantifying the Size and Duration of a Microburst-Producing Chorus Region on 5 December 2017. Geophys Res Lett 2022; 49:e2022GL099655. [PMID: 36247517 PMCID: PMC9540649 DOI: 10.1029/2022gl099655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Revised: 07/06/2022] [Accepted: 07/31/2022] [Indexed: 06/16/2023]
Abstract
Microbursts are impulsive (<1 s) injections of electrons into the atmosphere, thought to be caused by nonlinear scattering by chorus waves. Although attempts have been made to quantify their contribution to outer belt electron loss, the uncertainty in the overall size and duration of the microburst region is typically large, so that their contribution to outer belt loss is uncertain. We combine datasets that measure chorus waves (Van Allen Probes [RBSP], Arase, ground-based VLF stations) and microburst (>30 keV) precipitation (FIREBIRD II and AC6 CubeSats, POES) to determine the size of the microburst-producing chorus source region beginning on 5 December 2017. We estimate that the long-lasting (∼30 hr) microburst-producing chorus region extends from 4 to 8Δ MLT and 2-5Δ L. We conclude that microbursts likely represent a major loss source of outer radiation belt electrons for this event.
Collapse
Affiliation(s)
| | | | | | | | | | | | - M. Shumko
- NASA Goddard Space Flight CenterGreenbeltMDUSA
| | - J. Sample
- Montana State UniversityBozemanMTUSA
| | | | | | | | | | | | | | - T. Hori
- ISEENagoya UniversityNagoyaJapan
| | | | | | | | | | - M. Ozaki
- Kanazawa UniversityKanazawaJapan
| | - J. Manninen
- Sodankylä Geophysical ObservatoryUniversity of OuluSodankyläFinland
| |
Collapse
|
7
|
Miyoshi Y, Shinohara I, Ukhorskiy S, Claudepierre SG, Mitani T, Takashima T, Hori T, Santolik O, Kolmasova I, Matsuda S, Kasahara Y, Teramoto M, Katoh Y, Hikishima M, Kojima H, Kurita S, Imajo S, Higashio N, Kasahara S, Yokota S, Asamura K, Kazama Y, Wang SY, Jun CW, Kasaba Y, Kumamoto A, Tsuchiya F, Shoji M, Nakamura S, Kitahara M, Matsuoka A, Shiokawa K, Seki K, Nosé M, Takahashi K, Martinez-Calderon C, Hospodarsky G, Colpitts C, Kletzing C, Wygant J, Spence H, Baker DN, Reeves GD, Blake JB, Lanzerotti L. Collaborative Research Activities of the Arase and Van Allen Probes. Space Sci Rev 2022; 218:38. [PMID: 35757012 PMCID: PMC9213325 DOI: 10.1007/s11214-022-00885-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Accepted: 03/23/2022] [Indexed: 06/15/2023]
Abstract
This paper presents the highlights of joint observations of the inner magnetosphere by the Arase spacecraft, the Van Allen Probes spacecraft, and ground-based experiments integrated into spacecraft programs. The concurrent operation of the two missions in 2017-2019 facilitated the separation of the spatial and temporal structures of dynamic phenomena occurring in the inner magnetosphere. Because the orbital inclination angle of Arase is larger than that of Van Allen Probes, Arase collected observations at higher L -shells up to L ∼ 10 . After March 2017, similar variations in plasma and waves were detected by Van Allen Probes and Arase. We describe plasma wave observations at longitudinally separated locations in space and geomagnetically-conjugate locations in space and on the ground. The results of instrument intercalibrations between the two missions are also presented. Arase continued its normal operation after the scientific operation of Van Allen Probes completed in October 2019. The combined Van Allen Probes (2012-2019) and Arase (2017-present) observations will cover a full solar cycle. This will be the first comprehensive long-term observation of the inner magnetosphere and radiation belts.
Collapse
Affiliation(s)
- Y. Miyoshi
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601 Japan
| | - I. Shinohara
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, 252-5210 Japan
| | - S. Ukhorskiy
- Applied Physics Laboratory, The Johns Hopkins University, 11101 Johns Hopkins Rd, Laurel, MD 20723 USA
| | - S. G. Claudepierre
- Department of Atmospheric and Oceanic Sciences, University of California, Los Angeles, 7115 Math Sciences Bldg., Los Angeles, CA 90095 USA
| | - T. Mitani
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, 252-5210 Japan
| | - T. Takashima
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, 252-5210 Japan
| | - T. Hori
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601 Japan
| | - O. Santolik
- Faculty of Mathematics an Physics, Charles University, V Holesovickach 2, 18000 Prague, Czechia
- Dept. of Space Physics, Institute of Atmospheric Physics, Czech Academy of Sciences, Bocni II 1401, 14100 Prague, Czechia
| | - I. Kolmasova
- Faculty of Mathematics an Physics, Charles University, V Holesovickach 2, 18000 Prague, Czechia
- Dept. of Space Physics, Institute of Atmospheric Physics, Czech Academy of Sciences, Bocni II 1401, 14100 Prague, Czechia
| | - S. Matsuda
- Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa, 920-1192 Japan
| | - Y. Kasahara
- Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa, 920-1192 Japan
| | - M. Teramoto
- Graduate School of Engineering, Kyushu Institute of Technology, Kitakyusyu, 804-8550 Japan
| | - Y. Katoh
- Graduate School of Science, Tohoku University, Sendai, 980-8578 Japan
| | - M. Hikishima
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, 252-5210 Japan
| | - H. Kojima
- Research Institute for Sustainable Humanosphere, Kyoto University, Uji, 611-0011 Japan
| | - S. Kurita
- Research Institute for Sustainable Humanosphere, Kyoto University, Uji, 611-0011 Japan
| | - S. Imajo
- Graduate School of Science, Kyoto University, Kyoto, 606-8502 Japan
| | - N. Higashio
- Strategic Planning and Management Department, Japan Aerospace Exploration Agency, Tokyo, 101-8008 Japan
| | - S. Kasahara
- Graduate School of Science, University of Tokyo, Tokyo, 113-0033 Japan
| | - S. Yokota
- Graduate School of Science, Osaka University, Toyonaka, 560-0043 Japan
| | - K. Asamura
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, 252-5210 Japan
| | - Y. Kazama
- Institute of Astronomy and Astrophysics, Academia Sinica, No. 1, Sec. 4, Roosevelt Rd, Taipei, 10617 Taiwan
| | - S.-Y. Wang
- Institute of Astronomy and Astrophysics, Academia Sinica, No. 1, Sec. 4, Roosevelt Rd, Taipei, 10617 Taiwan
| | - C.-W. Jun
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601 Japan
| | - Y. Kasaba
- Graduate School of Science, Tohoku University, Sendai, 980-8578 Japan
| | - A. Kumamoto
- Graduate School of Science, Tohoku University, Sendai, 980-8578 Japan
| | - F. Tsuchiya
- Graduate School of Science, Tohoku University, Sendai, 980-8578 Japan
| | - M. Shoji
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601 Japan
| | - S. Nakamura
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601 Japan
- Institute for Advanced Research, Nagoya University, Nagoya, 464-8601 Japan
| | - M. Kitahara
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601 Japan
- Graduate School of Science, Tohoku University, Sendai, 980-8578 Japan
| | - A. Matsuoka
- Graduate School of Science, Kyoto University, Kyoto, 606-8502 Japan
| | - K. Shiokawa
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601 Japan
| | - K. Seki
- Graduate School of Science, University of Tokyo, Tokyo, 113-0033 Japan
| | - M. Nosé
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601 Japan
| | - K. Takahashi
- Applied Physics Laboratory, The Johns Hopkins University, 11101 Johns Hopkins Rd, Laurel, MD 20723 USA
| | - C. Martinez-Calderon
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601 Japan
| | - G. Hospodarsky
- Department of Physics and Astronomy, University of Iowa, Van Allen Hall (VAN), Iowa City, IA 52242 USA
| | - C. Colpitts
- School of Physics and Astronomy, University of Minnesota, 116 Church St. SE, Minneapolis, MN 55455 USA
| | - Craig Kletzing
- Department of Physics and Astronomy, University of Iowa, Van Allen Hall (VAN), Iowa City, IA 52242 USA
| | - J. Wygant
- School of Physics and Astronomy, University of Minnesota, 116 Church St. SE, Minneapolis, MN 55455 USA
| | - H. Spence
- Institute for the Study of Earth, Oceans, and Space, University of New Hampshire, 8 College Road, Durham, NH 03824 USA
| | - D. N. Baker
- Laboratory for Atmospheric and Space Physics, University of Colorado, 3665 Discovery Drive, 600 UCB, Boulder, CO 80303 USA
| | - G. D. Reeves
- Inteligence & Space Reserarch Division, Los Alamos National Laboratory, PO Box 1663, Los Alamos, NM USA
| | - J. B. Blake
- The Aerospace Corporation, P.O. Box 92957, Los Angeles, CA 90009-2957 USA
| | - L. Lanzerotti
- Department of Physics, New Jersey Institute of Technology, Newark, NJ 07102 USA
| |
Collapse
|
8
|
Miyoshi Y, Hosokawa K, Kurita S, Oyama SI, Ogawa Y, Saito S, Shinohara I, Kero A, Turunen E, Verronen PT, Kasahara S, Yokota S, Mitani T, Takashima T, Higashio N, Kasahara Y, Matsuda S, Tsuchiya F, Kumamoto A, Matsuoka A, Hori T, Keika K, Shoji M, Teramoto M, Imajo S, Jun C, Nakamura S. Penetration of MeV electrons into the mesosphere accompanying pulsating aurorae. Sci Rep 2021; 11:13724. [PMID: 34257336 PMCID: PMC8277844 DOI: 10.1038/s41598-021-92611-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 06/14/2021] [Indexed: 11/16/2022] Open
Abstract
Pulsating aurorae (PsA) are caused by the intermittent precipitations of magnetospheric electrons (energies of a few keV to a few tens of keV) through wave-particle interactions, thereby depositing most of their energy at altitudes ~ 100 km. However, the maximum energy of precipitated electrons and its impacts on the atmosphere are unknown. Herein, we report unique observations by the European Incoherent Scatter (EISCAT) radar showing electron precipitations ranging from a few hundred keV to a few MeV during a PsA associated with a weak geomagnetic storm. Simultaneously, the Arase spacecraft has observed intense whistler-mode chorus waves at the conjugate location along magnetic field lines. A computer simulation based on the EISCAT observations shows immediate catalytic ozone depletion at the mesospheric altitudes. Since PsA occurs frequently, often in daily basis, and extends its impact over large MLT areas, we anticipate that the PsA possesses a significant forcing to the mesospheric ozone chemistry in high latitudes through high energy electron precipitations. Therefore, the generation of PsA results in the depletion of mesospheric ozone through high-energy electron precipitations caused by whistler-mode chorus waves, which are similar to the well-known effect due to solar energetic protons triggered by solar flares.
Collapse
Affiliation(s)
- Y Miyoshi
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601, Japan.
| | - K Hosokawa
- Graduate School of Communication Engineering and Informatics, University of Electro-Communications, Chofu, 182-8585, Japan
| | - S Kurita
- Research Institute for Sustainable Humanosphere, Kyoto University, Uji, 611-0011, Japan
| | - S-I Oyama
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601, Japan.,National Institute of Polar Research, Tachikawa, 190-8518, Japan.,University of Oulu, Pentti Kaiteran katu 1, Linnanmaa, Oulu, Finland
| | - Y Ogawa
- National Institute of Polar Research, Tachikawa, 190-8518, Japan.,The Graduate University for Advanced Studies, SOKENDAI, Hayama, 240-0193, Japan.,Joint Support-Center for Data Science Research, Research Organization of Information and Systems, Tachikawa, 190-8518, Japan
| | - S Saito
- National Institute of Information and Communications Technology, Tokyo, 184-8795, Japan
| | - I Shinohara
- Japan Aerospace Exploration Agency (JAXA), Sagamihara, 252-5210, Japan
| | - A Kero
- Sodankylä Geophysical Observatory, University of Oulu, Sodankylä, Finland
| | - E Turunen
- Sodankylä Geophysical Observatory, University of Oulu, Sodankylä, Finland
| | - P T Verronen
- Sodankylä Geophysical Observatory, University of Oulu, Sodankylä, Finland.,Space and Earth Observation Centre, Finnish Meteorological Institute, Helsinki, Finland
| | - S Kasahara
- Graduate School of Science, University of Tokyo, Tokyo, 113-0033, Japan
| | - S Yokota
- Graduate School of Science, Osaka University, Toyonaka, 560-0043, Japan
| | - T Mitani
- Japan Aerospace Exploration Agency (JAXA), Sagamihara, 252-5210, Japan
| | - T Takashima
- Japan Aerospace Exploration Agency (JAXA), Sagamihara, 252-5210, Japan
| | - N Higashio
- Japan Aerospace Exploration Agency (JAXA), Sagamihara, 252-5210, Japan
| | - Y Kasahara
- Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa, 920-1192, Japan
| | - S Matsuda
- Japan Aerospace Exploration Agency (JAXA), Sagamihara, 252-5210, Japan
| | - F Tsuchiya
- Graduate School of Science, Tohoku University, Sendai, 980-8578, Japan
| | - A Kumamoto
- Graduate School of Science, Tohoku University, Sendai, 980-8578, Japan
| | - A Matsuoka
- Graduate School of Science, Kyoto University, Kyoto, 606-8502, Japan
| | - T Hori
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601, Japan
| | - K Keika
- Graduate School of Science, University of Tokyo, Tokyo, 113-0033, Japan
| | - M Shoji
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601, Japan
| | - M Teramoto
- Graduate School of Engineering, Kyushu Institute of Technology, Fukuoka, 820-8501, Japan
| | - S Imajo
- Graduate School of Science, Kyoto University, Kyoto, 606-8502, Japan
| | - C Jun
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601, Japan
| | - S Nakamura
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, 464-8601, Japan
| |
Collapse
|
9
|
Hayasaka N, Hirano A, Miyoshi Y, Tokuda IT, Yoshitane H, Matsuda J, Fukada Y. Correction: Salt-inducible kinase 3 regulates the mammalian circadian clock by destabilizing PER2 protein. eLife 2021; 10:66683. [PMID: 33492230 PMCID: PMC7834016 DOI: 10.7554/elife.66683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
10
|
Miyoshi Y, Ogawa O, Nishida A, Masuzawa M. Recurrent hyperglycemic hyperosmolar state after re-administration of dose-reduced ceritinib, an anaplastic lymphoma kinase inhibitor. Diabetol Int 2021; 12:126-129. [PMID: 33479588 DOI: 10.1007/s13340-020-00442-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Accepted: 05/27/2020] [Indexed: 11/25/2022]
Abstract
Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor with clinical activity in crizotinib-resistant ALK-positive non-small cell lung cancer and in treatment-naïve ALK-positive disease. Hyperglycemia is a known adverse event, but the mechanism by which ceritinib causes hyperglycemia is unknown, and whether ceritinib causes hyperglycemic emergencies is unclear. Here, we report the case of a patient with a hyperglycemic hyperosmolar state (HHS) recurrence after the re-administration of dose-reduced ceritinib. A 78-year-old man with type 2 diabetes diagnosed as having advanced lung adenocarcinoma had been treated with alogliptin (25 mg/day) for the diabetes and with ceritinib for the lung cancer. After 28 days of ceritinib administration, he was admitted to our hospital due to HHS. His blood glucose level improved with insulin therapy after discontinuation of the ceritinib. He then received re-administration with a decreased ceritinib dose while maintaining the insulin treatment to control his blood glucose, but his HHS recurred. We discontinued the ceritinib for other side effects and noticed the HHS disappeared. Our findings suggest that ceritinib can cause HHS and that HHS may recur even after dose reductions.
Collapse
Affiliation(s)
- Yuka Miyoshi
- Department of Diabetes and Endocrinology, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602 Japan.,Department of Preventive Medicine and Public Health, National Defense Medical College, Tokorozawa, Saitama Japan
| | - Osamu Ogawa
- Department of Diabetes and Endocrinology, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602 Japan
| | - Ai Nishida
- Department of General Internal Medicine, Kameda Medical Center, Kamogawa, Chiba Japan
| | - Masahiro Masuzawa
- Department of Diabetes and Endocrinology, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602 Japan
| |
Collapse
|
11
|
Nosé M, Matsuoka A, Kumamoto A, Kasahara Y, Teramoto M, Kurita S, Goldstein J, Kistler LM, Singh S, Gololobov A, Shiokawa K, Imajo S, Oimatsu S, Yamamoto K, Obana Y, Shoji M, Tsuchiya F, Shinohara I, Miyoshi Y, Kurth WS, Kletzing CA, Smith CW, MacDowall RJ, Spence H, Reeves GD. Oxygen torus and its coincidence with EMIC wave in the deep inner magnetosphere: Van Allen Probe B and Arase observations. Earth Planets Space 2020; 72:111. [PMID: 32831576 PMCID: PMC7410109 DOI: 10.1186/s40623-020-01235-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/22/2020] [Accepted: 07/17/2020] [Indexed: 06/11/2023]
Abstract
We investigate the longitudinal structure of the oxygen torus in the inner magnetosphere for a specific event found on 12 September 2017, using simultaneous observations from the Van Allen Probe B and Arase satellites. It is found that Probe B observed a clear enhancement in the average plasma mass (M) up to 3-4 amu at L = 3.3-3.6 and magnetic local time (MLT) = 9.0 h. In the afternoon sector at MLT ~ 16.0 h, both Probe B and Arase found no clear enhancements in M. This result suggests that the oxygen torus does not extend over all MLT but is skewed toward the dawn. Since a similar result has been reported for another event of the oxygen torus in a previous study, a crescent-shaped torus or a pinched torus centered around dawn may be a general feature of the O+ density enhancement in the inner magnetosphere. We newly find that an electromagnetic ion cyclotron (EMIC) wave in the H+ band appeared coincidently with the oxygen torus. From the lower cutoff frequency of the EMIC wave, the ion composition of the oxygen torus is estimated to be 80.6% H+, 3.4% He+, and 16.0% O+. According to the linearized dispersion relation for EMIC waves, both He+ and O+ ions inhibit EMIC wave growth and the stabilizing effect is stronger for He+ than O+. Therefore, when the H+ fraction or M is constant, the denser O+ ions are naturally accompanied by the more tenuous He+ ions, resulting in a weaker stabilizing effect (i.e., larger growth rate). From the Probe B observations, we find that the growth rate becomes larger in the oxygen torus than in the adjacent regions in the plasma trough and the plasmasphere.
Collapse
Affiliation(s)
- M. Nosé
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - A. Matsuoka
- Graduate School of Science, Kyoto University, Kyoto, Japan
| | - A. Kumamoto
- Graduate School of Science, Tohoku University, Sendai, Japan
| | - Y. Kasahara
- Advanced Research Center for Space Science and Technology, Kanazawa University, Kanazawa, Japan
| | - M. Teramoto
- Department of Space Systems Engineering, Kyushu Institute of Technology, Kitakyusyu, Japan
| | - S. Kurita
- Research Institute for Sustainable Humanosphere, Kyoto University, Uji, Japan
| | - J. Goldstein
- Space Science and Engineering Division, Southwest Research Institute, San Antonio, TX USA
- University of Texas at San Antonio, San Antonio, TX USA
| | - L. M. Kistler
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
- Institute for the Study of Earth, Oceans, and Space, University of New Hampshire, Durham, NH USA
| | - S. Singh
- Indian Institute of Geomagnetism, Navi Mumbai, India
| | - A. Gololobov
- North-Eastern Federal University, Yakutsk, Russia
| | - K. Shiokawa
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - S. Imajo
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - S. Oimatsu
- Graduate School of Science, Kyoto University, Kyoto, Japan
| | - K. Yamamoto
- Graduate School of Science, The University of Tokyo, Tokyo, Japan
| | - Y. Obana
- Faculty of Engineering, Osaka Electro-Communication University, Neyagawa, Japan
| | - M. Shoji
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - F. Tsuchiya
- Graduate School of Science, Tohoku University, Sendai, Japan
| | - I. Shinohara
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, Japan
| | - Y. Miyoshi
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - W. S. Kurth
- Department of Physics and Astronomy, University of Iowa, Iowa City, IA USA
| | - C. A. Kletzing
- Department of Physics and Astronomy, University of Iowa, Iowa City, IA USA
| | - C. W. Smith
- Institute for the Study of Earth, Oceans, and Space, University of New Hampshire, Durham, NH USA
| | - R. J. MacDowall
- Solar System Exploration Division, Goddard Space Flight Center, Greenbelt, MD USA
| | - H. Spence
- Institute for the Study of Earth, Oceans, and Space, University of New Hampshire, Durham, NH USA
| | - G. D. Reeves
- Space Sciences and Applications Group, Los Alamos National Laboratory, Los Alamos, NM USA
| |
Collapse
|
12
|
Kise T, Takamasu E, Miyoshi Y, Yokogawa N, Shimada K. THU0309 UNILATERAL TEMPORAL ARTERY BIOPSY IS SUFFICIENT FOR DIAGNOSING GIANT CELL ARTERITIS IF THE SERUM C-REACTIVE PROTEIN LEVEL IS 10 MG/DL OR HIGHER. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Temporal artery biopsy (TAB) is the gold standard for diagnosing giant cell arteritis (GCA). However, previous studies have reported that the discordance rate of TAB is 3-45%,i.e., in unliteral TAB, GCA may be overlooked in one in five patients, approximately. Evidence as to whether bilateral TAB should be performed initially or one-sided TAB is sufficient for diagnosing GCA is lacking.Objectives:To investigate the predictors of patients with GCA in whom one-sided TAB is sufficient.Methods:The present study was a cross-sectional, single center study conducted from April 1, 2011 to July 31, 2019 at Tokyo Metropolitan Tama Medical Center. Of all consecutive GCA cases for which bilateral TAB was performed, bilaterally positive cases and unilaterally positive cases were extracted as bilateral positive group (BPG) and unilateral positive group (UPG), respectively. GCA was defined in accordance with the classification criteria of the 1990 American College of Rheumatology, and GCA was diagnosed if no other etiology was found within six months after beginning of high-dose glucocorticoid treatment. Demographic, clinical and laboratory data were obtained from the medical records, and the BPG and the UPG were compared statistically in each variable. Statistical significance was defined asp< 0.05.Results:During study, 264 biopsies were performed for 145 cases, who suspected GCA and underwent TAB. The pathological positivity rate was 26.1% (68 / 264 biopsies). Of these, 53 cases had final diagnosis of GCA, in which 43 cases were biopsy proven GCA. Thirty-seven biopsy proven GCA with bilateral TAB were enrolled; 64.9% women; mean (SD) age 75 (8.9) years; median [IQR] TAB length 17.5 [13.0,20.0] mm; headache 54.1%; jaw claudication 45.9%; scalp tenderness 16.2%; temporal artery (TA) tenderness 32.4%; TA engorgement 32.4%; TA pulse abnormality 5.4%; visual symptoms 2.7%; a fever of 38.5°C or higher 40.5%; shoulder girdle pain 48.6%; imaging of aortitis or arteritis 40.5%; median [IQR] white blood cell 9,100 [7200, 12050] /μl; median [IQR] platelet cell 37.5 [27.0, 46.3] ×104/μl; median [IQR] C-reactive protein (CRP) 10.1 [3.9, 16.5] mg/dL; erythrocyte sedimentation rate [IQR] 105 [66, 129] mm/h. Thirty-one in 37 cases were positive bilaterally while 6 in 37 cases were positive unilaterally; and the discordance rate was 16.2%. The median sample length after formalin fixation was 19.0 mm for the BPG and 14.5 mm for the UPG (p= 0.171). The parameters above were compared between UPG and BPG. Of these, only the serum CRP value (mg/dL) differed statistically between groups, and the median value of the two groups was 10.6 and 6.5, respectively (median test:p= 0.031). To predict BPG, in whom unilateral TAB is sufficient for diagnosing GCA, the cut-off value of serum CRP with a specificity of 100% and a sensitivity of 61.3% was set at 9.3 mg/dL (ROC analysis: AUC 0.726).Conclusion:When the serum CRP level is 10 mg/dL or higher in GCA suspected patients, an unilateral TAB alone was sufficient for an accurate diagnosis.References:[1]Hellmich, B, et al.Ann Rheum Dis2020;79(1):19-30.[2]Breuer, GS, et al.J Rheumatol. 2009;36(4):794-796.[3]Czyz CN, et al.Vascular2019;27(4):347-351.[4]Durling B, et al.Can J Ophthalmol2014;49(2):157-161.Figure.Comparison of median CRP levels between unilaterally positive group and bilaterally positive group.Disclosure of Interests:None declared
Collapse
|
13
|
Goto M, Yokogawa N, Miyoshi Y, Shimada K. SAT0208 INCIDENCES OF ADVERSE EFFECTS AND DISEASE FLARE DUE TO PNEUMOCYSTIS PNEUMONIA PROPHYLAXIS WITH TRIMETHOPRIM/SULFAMETHOXAZOLE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4551] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Methods of preventing pneumocystis pneumonia (PCP) in systemic lupus erythematosus (SLE) are controversial. Previous studies have verified the efficacy and safety of trimethoprim/sulfamethoxazole (TMP-SMX) in patients with rheumatic diseases1. However, as for SLE, some clinicians advise against prescribing TMP-SMX because sulfa allergy is reportedly more common in SLE than in other rheumatic diseases2, 3. Anecdotally, sulfonamides may also worsen SLE itself, but few data are available on lupus flares related to sulfonamides3.Objectives:This study aimed to assess the incidences of adverse effects and disease flare due to PCP prophylaxis with TMP-SMX in SLE patients.Methods:SLE patients seen at our hospital between September 2010 and April 2018 who received TMP-SMX as a PCP prophylaxis were enrolled. The clinical manifestations, treatment course, adverse drug reactions, and occurrence of lupus flares were retrospectively assessed from the medical records. The Naranjo adverse drug reaction probability scale4 was used to determine whether the reactions were induced by SMX-TMP. According to the British Isles Lupus Assessment Group (BILAG) 2004 index, a severe flare of lupus was defined as a development of a new grade A manifestation, and a moderate flare as a development of grade B manifestation following grade C, D or E. Two board-certificated rheumatologists reviewed the medical records in a blinded fashion to determine the reason for the flare, with disagreement resolved by consensus.Results:In total, 188 SLE patients were enrolled; of these, 117 (62.2%) had no adverse events and were able to continue taking SMX-TMP as needed. Seventy-one patients (37.8%) stopped SMX-TMP due to suspected adverse drug reactions, including fever, rash, liver function disorder, and cytopenia. The Naranjo scale indicated “definite” in 4, “probable” in 39, and “possible” in 28. Eighteen-patients restarted the SMX-TMP and 9 patients could continue the prophylaxis without adverse effects. Five patients were hospitalized to treat the adverse events: 3 with drug rash (concomitant use of hydroxychloroquine in 2), 1 with hypersensitivity (concomitant use of azathioprine) and 1 with hyponatremia, respectively.Lupus flares occurred in 10 patients (5.3%) within one month after the start of the the SMX-TMP prophylaxis. Macrophage activation syndrome (MAS) or neuropsychiatric SLE occurred in 9 of them. Of 188 cases, 2 patients (1.1%) developed a new onset of MAS during the stable clinical course as the flare, which was considered due to SMX-TMP. Confounding factors, including high disease activity and the reduction of glucocorticoids, were identified in other 8 flares.Conclusion:PCP prophylaxis with SMX-TMP was tolerable in most SLE patients. However, a small number of SLE patients developed severe adverse effects or disease flares due to the SMX-TMP.References:[1]Park JW, et al. Annals of the Rheumatic Diseases 2018;77:644-649.[2]Suyama Y, et al. Modern Rheumatology 2016;26:557-61[3]Petri M, et al. Journal of Rheumatology 1992;19:265-9[4]Naranjo CA, et al. Clinical Pharmacology and Therapeutics 1981;30:239-45Disclosure of Interests:None declared
Collapse
|
14
|
Nakazawa Y, Hara Y, Oka Y, Komine O, van den Heuvel D, Guo C, Daigaku Y, Isono M, He Y, Shimada M, Kato K, Jia N, Hashimoto S, Kotani Y, Miyoshi Y, Tanaka M, Sobue A, Mitsutake N, Suganami T, Masuda A, Ohno K, Nakada S, Mashimo T, Yamanaka K, Luijsterburg MS, Ogi T. Ubiquitination of DNA Damage-Stalled RNAPII Promotes Transcription-Coupled Repair. Cell 2020; 180:1228-1244.e24. [PMID: 32142649 DOI: 10.1016/j.cell.2020.02.010] [Citation(s) in RCA: 107] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Revised: 12/16/2019] [Accepted: 02/04/2020] [Indexed: 02/06/2023]
Abstract
Transcription-coupled nucleotide excision repair (TC-NER) is initiated by the stalling of elongating RNA polymerase II (RNAPIIo) at DNA lesions. The ubiquitination of RNAPIIo in response to DNA damage is an evolutionarily conserved event, but its function in mammals is unknown. Here, we identified a single DNA damage-induced ubiquitination site in RNAPII at RPB1-K1268, which regulates transcription recovery and DNA damage resistance. Mechanistically, RPB1-K1268 ubiquitination stimulates the association of the core-TFIIH complex with stalled RNAPIIo through a transfer mechanism that also involves UVSSA-K414 ubiquitination. We developed a strand-specific ChIP-seq method, which revealed RPB1-K1268 ubiquitination is important for repair and the resolution of transcriptional bottlenecks at DNA lesions. Finally, RPB1-K1268R knockin mice displayed a short life-span, premature aging, and neurodegeneration. Our results reveal RNAPII ubiquitination provides a two-tier protection mechanism by activating TC-NER and, in parallel, the processing of DNA damage-stalled RNAPIIo, which together prevent prolonged transcription arrest and protect against neurodegeneration.
Collapse
Affiliation(s)
- Yuka Nakazawa
- Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Human Genetics and Molecular Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yuichiro Hara
- Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Human Genetics and Molecular Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yasuyoshi Oka
- Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Human Genetics and Molecular Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Okiru Komine
- Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Neuroscience and Pathobiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Diana van den Heuvel
- Department of Human Genetics, Leiden University Medical Center (LUMC), Leiden, the Netherlands
| | - Chaowan Guo
- Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Human Genetics and Molecular Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yasukazu Daigaku
- Frontier Research Institute for Interdisciplinary Sciences, Tohoku University, Sendai, Japan; Graduate School of Life Sciences, Tohoku University, Sendai, Japan
| | - Mayu Isono
- Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Human Genetics and Molecular Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yuxi He
- Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Human Genetics and Molecular Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Mayuko Shimada
- Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Human Genetics and Molecular Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Kana Kato
- Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Human Genetics and Molecular Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Nan Jia
- Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Human Genetics and Molecular Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Satoru Hashimoto
- Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Human Genetics and Molecular Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yuko Kotani
- Institute of Experimental Animal Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan; Genome Editing Research and Development (R&D) Center, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Yuka Miyoshi
- Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Neuroscience and Pathobiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Miyako Tanaka
- Department of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Immunometabolism, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Akira Sobue
- Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Neuroscience and Pathobiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Norisato Mitsutake
- Department of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
| | - Takayoshi Suganami
- Department of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Immunometabolism, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Akio Masuda
- Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Kinji Ohno
- Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Shinichiro Nakada
- Department of Bioregulation and Cellular Response, Graduate School of Medicine, Osaka University, Osaka, Japan; Institute for Advanced Co-Creation Studies, Osaka University, Osaka, Japan
| | - Tomoji Mashimo
- Institute of Experimental Animal Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan; Genome Editing Research and Development (R&D) Center, Graduate School of Medicine, Osaka University, Osaka, Japan; Division of Animal Genetics, Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Koji Yamanaka
- Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Neuroscience and Pathobiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Martijn S Luijsterburg
- Department of Human Genetics, Leiden University Medical Center (LUMC), Leiden, the Netherlands
| | - Tomoo Ogi
- Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan; Department of Human Genetics and Molecular Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
| |
Collapse
|
15
|
Hosokawa K, Miyoshi Y, Ozaki M, Oyama SI, Ogawa Y, Kurita S, Kasahara Y, Kasaba Y, Yagitani S, Matsuda S, Tsuchiya F, Kumamoto A, Kataoka R, Shiokawa K, Raita T, Turunen E, Takashima T, Shinohara I, Fujii R. Multiple time-scale beats in aurora: precise orchestration via magnetospheric chorus waves. Sci Rep 2020; 10:3380. [PMID: 32098993 PMCID: PMC7042315 DOI: 10.1038/s41598-020-59642-8] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Accepted: 01/31/2020] [Indexed: 11/26/2022] Open
Abstract
The brightness of aurorae in Earth’s polar region often beats with periods ranging from sub-second to a few tens of a second. Past observations showed that the beat of the aurora is composed of a superposition of two independent periodicities that co-exist hierarchically. However, the origin of such multiple time-scale beats in aurora remains poorly understood due to a lack of measurements with sufficiently high temporal resolution. By coordinating experiments using ultrafast auroral imagers deployed in the Arctic with the newly-launched magnetospheric satellite Arase, we succeeded in identifying an excellent agreement between the beats in aurorae and intensity modulations of natural electromagnetic waves in space called “chorus”. In particular, sub-second scintillations of aurorae are precisely controlled by fine-scale chirping rhythms in chorus. The observation of this striking correlation demonstrates that resonant interaction between energetic electrons and chorus waves in magnetospheres orchestrates the complex behavior of aurora on Earth and other magnetized planets.
Collapse
Affiliation(s)
- K Hosokawa
- Graduate School of Informatics and Engineering, University of Electro-Communications, Chofu, Tokyo, Japan. .,Center for Space Science and Radio Engineering, University of Electro-Communications, Chofu, Tokyo, Japan.
| | - Y Miyoshi
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Aichi, Japan
| | - M Ozaki
- Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa, Ishikawa, Japan
| | - S-I Oyama
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Aichi, Japan.,National Institute of Polar Research, Tachikawa, Tokyo, Japan.,Ionospheric Physics Research Unit, University of Oulu, Oulu, Finland
| | - Y Ogawa
- National Institute of Polar Research, Tachikawa, Tokyo, Japan.,The Graduate University for Advanced Studies, Hayama, Kanagawa, Japan
| | - S Kurita
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Aichi, Japan
| | - Y Kasahara
- Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa, Ishikawa, Japan
| | - Y Kasaba
- Department of Geophysics, Graduate School of Science, Tohoku University, Sendai, Miyagi, Japan
| | - S Yagitani
- Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa, Ishikawa, Japan
| | - S Matsuda
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, Kanagawa, Japan
| | - F Tsuchiya
- Department of Geophysics, Graduate School of Science, Tohoku University, Sendai, Miyagi, Japan
| | - A Kumamoto
- Department of Geophysics, Graduate School of Science, Tohoku University, Sendai, Miyagi, Japan
| | - R Kataoka
- National Institute of Polar Research, Tachikawa, Tokyo, Japan.,The Graduate University for Advanced Studies, Hayama, Kanagawa, Japan
| | - K Shiokawa
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Aichi, Japan
| | - T Raita
- Sodankylä Geophysical Observatory, University of Oulu, Sodankylä, Finland
| | - E Turunen
- Sodankylä Geophysical Observatory, University of Oulu, Sodankylä, Finland
| | - T Takashima
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, Kanagawa, Japan
| | - I Shinohara
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, Kanagawa, Japan
| | - R Fujii
- Research Organization of Information and Systems, Tokyo, Japan
| |
Collapse
|
16
|
Miki M, Takao S, Konishi M, Shigeoka Y, Miyashita M, Suwa H, Imamura M, Okuno T, Hirokaga K, Miyoshi Y, Murase K, Yanai A, Yamagami K, Akazawa K. Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz418.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Hiwatari R, Katayama K, Nakamura M, Miyoshi Y, Aoki A, Asakura N, Utoh H, Homma Y, Tokunaga S, Nakajima N, Someya Y, Sakamoto Y, Tobita K. Development of plant concept related to tritium handling in the water-cooling system for JA DEMO. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.03.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
18
|
Fujimoto Y, Higuchi T, Watanabe T, Hida AI, Imamura M, Kitajima K, Miyoshi Y. Abstract P2-08-35: A significance of SUVmax levels on FDG-PET as a prognostic factor may be mediated by local immune environment of breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
(Background) SUVmax levels (maximum radioactivity concentration per a pixel) on FDG-PET reflect glucose uptake and it is clinically useful as a prognostic factor. It is reported that breast cancer with high levels of SUVmax causes insufficient glucose concentration in stromal tissue, which results in suppressed cytotoxic T-lymphocytes function. These data may indicate that the prognostic significance of SUVmax levels is influenced by local immune environment of breast cancer. The aim of this study is to investigate whether local immune responses of breast cancer affect correlation of SUVmax levels and prognosis.
(Method) The 278 invasive breast cancer patients were recruited who underwent surgery at Hyogo College of Medicine Hospital and whose SUVmax levels in the breast were examined before surgery or neo-adjuvant therapy. The cutoff value of SUVmax levels was set at 3.585. Tumor infiltrate lymphocytes (TILs) were evaluated as a local immune response and the distributions of TILs were divided into three groups, inflamed (intra-tumoral lymphocytes, Inf), immune excluded (peri-tumoral lymphocytes, IE) and immune desert (very few lymphocytes, ID). During follow-up period (median 39 months), 21 patients relapsed.
(Results) Relapse free survival (RFS) in the SUVmax-high group was significantly worse than in the SUVmax–low group (p=0.0026). There was no correlation between TILs distribution patterns and RFS. In the IE+ID group (175 patients) SUVmax levels were not correlated with prognosis, but in the Inf group (103 patients) RFS of SUVmax-high was significantly worse than of SUVmax-low (p=0.0051). In the multivariate analysis including nodal status and nuclear grade, SUVmax levels of the Inf group was an independent prognostic factor.
(Discussion and conclusion) SUVmax levels in primary lesions were correlated with prognosis only in the Inf group and were not in the IE+ID group. A significance of SUVmax levels as a prognostic factor may be diverse depending on the local immune environment of breast cancer. A novel therapeutic strategy such as inducing suppression of glucose uptake in cancer cells is suggested for breast cancer with immune inflamed.
Citation Format: Fujimoto Y, Higuchi T, Watanabe T, Hida AI, Imamura M, Kitajima K, Miyoshi Y. A significance of SUVmax levels on FDG-PET as a prognostic factor may be mediated by local immune environment of breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-35.
Collapse
Affiliation(s)
- Y Fujimoto
- Hyogo Colloge of Medicine, Nishinomiya, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
| | - T Higuchi
- Hyogo Colloge of Medicine, Nishinomiya, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
| | - T Watanabe
- Hyogo Colloge of Medicine, Nishinomiya, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
| | - AI Hida
- Hyogo Colloge of Medicine, Nishinomiya, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
| | - M Imamura
- Hyogo Colloge of Medicine, Nishinomiya, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
| | - K Kitajima
- Hyogo Colloge of Medicine, Nishinomiya, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
| | - Y Miyoshi
- Hyogo Colloge of Medicine, Nishinomiya, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
| |
Collapse
|
19
|
Imamura M, Morimoto T, Egawa C, Miyagawa Y, Miyoshi Y. Abstract P3-10-19: Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive locally advanced and metastatic breast cancer treated with trastuzumab emtansine. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-10-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose The prognosis of human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancers (MBCs) has dramatically improved due to the introduction of trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1). The efficacy of T-DM1 is prolonged for some patients; however, the predictive factors remain unknown. There is a report that T-DM1 induced antitumor immunity in patients treated with neoadjuvant therapy, with tumor infiltrating lymphocytes (TILs) increasing after the administration of T-DM1. Based on these observations, the benefits of T-DM1 for prognosis may be mediated by an immune reaction against breast cancers, at least in part. As an indicator of cancer immunity, in addition to TILs, the neutrophil-to-lymphocyte ratio (NLR) has been established in early breast cancers. In the present study, we investigated the usefulness of the NLR for treatment efficacy of T-DM1 in HER2-positive MBCs. Methods Fifty-three advanced or metastatic breast cancers treated with T-DM1 were retrospectively recruited from three institutes. The NLR in the peripheral blood was measured at baseline (just before the start of T-DM1) and after one cycle (just before the start of cycle 2). The cutoff value of the NLR was set at 2.56 (median value) and progression-free survival (PFS) and overall survival (OS) according to NLR levels were evaluated. Results The PFS of patients with NLR-low at baseline (NLR<2.56; n=26; median, not reached) was significantly better than that of patients with NLR-high (NLR≥2.56; n=27; median, 4.13 months; hazard ratio [HR], 0.226; 95% confidence interval [CI], 0.112-0.493; p=0.0001). There was a significant association between improved OS and a low NLR (HR, 0.384; 95% CI, 0.170-0.910; p=0.0296). In the subgroup analysis, patients with NLR-low consistently had improved PFS compared to those with NLR-high irrespective of the number of prior chemotherapy regimens, prior trastuzumab use, visceral metastasis, estrogen receptor status, and HER2 immunohistochemical staining score. According to univariable analysis of each clinical and biological factor for PFS, the NLR-low group was solely and significantly associated with favorable PFS compared with the NLR-high group (HR, 0.226; 95% CI, 0.112-0.493; p=0.0001). The NLR at baseline was significantly decreased (p=0.0010) and lymphocyte count was significantly increased after one cycle treatment (p=0.0005). Interestingly, the PFS of patients whose NLR was high at baseline but changed to low after one cycle (n=12; median PFS, 6.47 months) was better than that of patients with a consistently high NLR (n=14; median PFS, 3.27 months). Conclusion and Discussion A low baseline NLR was found to be significantly associated with improved PFS for patients treated with T-DM1. Interestingly, lymphocyte count was significantly increased in patients in the NLR-low group but not in the NLR-high group after one cycle treatment. Although detailed mechanisms remain unknown, the treatment efficacy of T-DM1 may be partly mediated by immunoreaction on the basis of present data. A low baseline NLR appears to be beneficial for treatment with T-DM1 in HER2-positive breast cancers.
Citation Format: Imamura M, Morimoto T, Egawa C, Miyagawa Y, Miyoshi Y. Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive locally advanced and metastatic breast cancer treated with trastuzumab emtansine [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-10-19.
Collapse
Affiliation(s)
- M Imamura
- Hyogo College of Medicine, Nishinomiya, Japan; Yao Municipal Hospital, Yao, Japan; Kansai Hosai Hospital, Nishinomiya, Japan
| | - T Morimoto
- Hyogo College of Medicine, Nishinomiya, Japan; Yao Municipal Hospital, Yao, Japan; Kansai Hosai Hospital, Nishinomiya, Japan
| | - C Egawa
- Hyogo College of Medicine, Nishinomiya, Japan; Yao Municipal Hospital, Yao, Japan; Kansai Hosai Hospital, Nishinomiya, Japan
| | - Y Miyagawa
- Hyogo College of Medicine, Nishinomiya, Japan; Yao Municipal Hospital, Yao, Japan; Kansai Hosai Hospital, Nishinomiya, Japan
| | - Y Miyoshi
- Hyogo College of Medicine, Nishinomiya, Japan; Yao Municipal Hospital, Yao, Japan; Kansai Hosai Hospital, Nishinomiya, Japan
| |
Collapse
|
20
|
Tanino H, Suzuki M, Kaise H, Miyashita M, Chishima T, Hayashi M, Miyoshi Y, Futamura M, Ohtani S, Nagahashi M, Ohta T, Kosaka Y, Ishikawa T, Hasegawa Y, Kubota T, Sangai T, Iwatani T, Yamada A, Akazawa K, Kohno N. Abstract OT1-05-04: Phase 3 trial of carboplatin in triple negative breast cancer (TNBC) patients with residual invasive carcinoma after neoadjuvant chemotherapy ( JONIE4:J-CAT trial). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-05-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: It is well known that the prognosis of non pCR TNBC patients was poor after anthracycline and taxan treatment. For such patients, capecitabine seems to be effective to reduce recurrence based on the HR 0.58 of the CREATE X trial (Masuda, N. et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 376, 2147. 2017) . However, the target of capecitabine is still unclear for TNBC. We classified non pCR tumors as BRCAness and Sporadic using BRCAness test(MRC-Holland, Amsterdam, the Netherlands). The recurrence rate of the BRCAness group was about 70%. Carboplatine is expected to be effective against BRCAness tumors, as it is a DNA damaging agent. In this study BRCAness can be checked just before carboplatin treatment using surgical specimens. Then the efficacy of carboplatin will be directly known to make comparison between DFS in the carboplatin group and that of the observation group.
Trial design: This is anopen label, randomized phase III study that will enroll TNBC with residual invasive cancer after surgery with preoperative chemotherapy including both anthracycrine and taxan. Patients are randomly assigned to either the carboplatin group or observation group. The patients in the carboplatin group are treated with carboplatin at AUC 6 and those in the observation group are observed at only 3 years.
Eligibility criteria:
1) ER and PgR<1%, HER2 0, 1+ or 2+ with FISH negative on core needle biopsy before the chemotherapy and surgical specimens.
2) Preoperative chemotherapy including both anthracycrine and taxan.
3) Residual invasive cancer on breast tumors or lymph node metastasis in surgical specimens.
4) 20-79 year old women.
5) No chemotherapy within 5 years.
6) Not bilateral breast cancer, without metastasis, no prior breast cancer.
7) No severe bone marrow suppression.
Specific aims:Primary objective is DFS (Disease Free Survival). Secondary objectives are overall survival and safety.
STATISTICAL METHODS:
The 3 years recurrence rate of the observation group was estimated as 40% and hazard ratio at 0.58 based on the CREATE X trial. For both groups, 135 patients are necessary. This study is powered to approximately 80% to test the superiority of carboplatin group at a 2-sided α=0.05 using a stratified log-rank test.
Activation Date:22ndMarch 2018. No patients had been enrolled till 3rd July.
Citation Format: Tanino H, Suzuki M, Kaise H, Miyashita M, Chishima T, Hayashi M, Miyoshi Y, Futamura M, Ohtani S, Nagahashi M, Ohta T, Kosaka Y, Ishikawa T, Hasegawa Y, Kubota T, Sangai T, Iwatani T, Yamada A, Akazawa K, Kohno N. Phase 3 trial of carboplatin in triple negative breast cancer (TNBC) patients with residual invasive carcinoma after neoadjuvant chemotherapy (JONIE4:J-CAT trial) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-05-04.
Collapse
Affiliation(s)
- H Tanino
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Suzuki
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - H Kaise
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Miyashita
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Chishima
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Hayashi
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - Y Miyoshi
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Futamura
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - S Ohtani
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Nagahashi
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Ohta
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - Y Kosaka
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Ishikawa
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - Y Hasegawa
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Kubota
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Sangai
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Iwatani
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - A Yamada
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - K Akazawa
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - N Kohno
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| |
Collapse
|
21
|
Angelopoulos V, Cruce P, Drozdov A, Grimes EW, Hatzigeorgiu N, King DA, Larson D, Lewis JW, McTiernan JM, Roberts DA, Russell CL, Hori T, Kasahara Y, Kumamoto A, Matsuoka A, Miyashita Y, Miyoshi Y, Shinohara I, Teramoto M, Faden JB, Halford AJ, McCarthy M, Millan RM, Sample JG, Smith DM, Woodger LA, Masson A, Narock AA, Asamura K, Chang TF, Chiang CY, Kazama Y, Keika K, Matsuda S, Segawa T, Seki K, Shoji M, Tam SWY, Umemura N, Wang BJ, Wang SY, Redmon R, Rodriguez JV, Singer HJ, Vandegriff J, Abe S, Nose M, Shinbori A, Tanaka YM, UeNo S, Andersson L, Dunn P, Fowler C, Halekas JS, Hara T, Harada Y, Lee CO, Lillis R, Mitchell DL, Argall MR, Bromund K, Burch JL, Cohen IJ, Galloy M, Giles B, Jaynes AN, Le Contel O, Oka M, Phan TD, Walsh BM, Westlake J, Wilder FD, Bale SD, Livi R, Pulupa M, Whittlesey P, DeWolfe A, Harter B, Lucas E, Auster U, Bonnell JW, Cully CM, Donovan E, Ergun RE, Frey HU, Jackel B, Keiling A, Korth H, McFadden JP, Nishimura Y, Plaschke F, Robert P, Turner DL, Weygand JM, Candey RM, Johnson RC, Kovalick T, Liu MH, McGuire RE, Breneman A, Kersten K, Schroeder P. The Space Physics Environment Data Analysis System (SPEDAS). Space Sci Rev 2019; 215:9. [PMID: 30880847 PMCID: PMC6380193 DOI: 10.1007/s11214-018-0576-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Accepted: 12/29/2018] [Indexed: 05/31/2023]
Abstract
With the advent of the Heliophysics/Geospace System Observatory (H/GSO), a complement of multi-spacecraft missions and ground-based observatories to study the space environment, data retrieval, analysis, and visualization of space physics data can be daunting. The Space Physics Environment Data Analysis System (SPEDAS), a grass-roots software development platform (www.spedas.org), is now officially supported by NASA Heliophysics as part of its data environment infrastructure. It serves more than a dozen space missions and ground observatories and can integrate the full complement of past and upcoming space physics missions with minimal resources, following clear, simple, and well-proven guidelines. Free, modular and configurable to the needs of individual missions, it works in both command-line (ideal for experienced users) and Graphical User Interface (GUI) mode (reducing the learning curve for first-time users). Both options have "crib-sheets," user-command sequences in ASCII format that can facilitate record-and-repeat actions, especially for complex operations and plotting. Crib-sheets enhance scientific interactions, as users can move rapidly and accurately from exchanges of technical information on data processing to efficient discussions regarding data interpretation and science. SPEDAS can readily query and ingest all International Solar Terrestrial Physics (ISTP)-compatible products from the Space Physics Data Facility (SPDF), enabling access to a vast collection of historic and current mission data. The planned incorporation of Heliophysics Application Programmer's Interface (HAPI) standards will facilitate data ingestion from distributed datasets that adhere to these standards. Although SPEDAS is currently Interactive Data Language (IDL)-based (and interfaces to Java-based tools such as Autoplot), efforts are under-way to expand it further to work with python (first as an interface tool and potentially even receiving an under-the-hood replacement). We review the SPEDAS development history, goals, and current implementation. We explain its "modes of use" with examples geared for users and outline its technical implementation and requirements with software developers in mind. We also describe SPEDAS personnel and software management, interfaces with other organizations, resources and support structure available to the community, and future development plans. ELECTRONIC SUPPLEMENTARY MATERIAL The online version of this article (10.1007/s11214-018-0576-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- V. Angelopoulos
- Department of Earth, Planetary and Space Sciences, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, USA
| | - P. Cruce
- Department of Earth, Planetary and Space Sciences, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, USA
| | - A. Drozdov
- Department of Earth, Planetary and Space Sciences, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, USA
| | - E. W. Grimes
- Department of Earth, Planetary and Space Sciences, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, USA
| | - N. Hatzigeorgiu
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - D. A. King
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - D. Larson
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - J. W. Lewis
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - J. M. McTiernan
- Space Sciences Laboratory, University of California, Berkeley, USA
| | | | - C. L. Russell
- Department of Earth, Planetary and Space Sciences, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, USA
| | - T. Hori
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | | | - A. Kumamoto
- Tohoku University, 6-3, Aoba, Aramaki, Aoba Sendai, 980-8578 Japan
| | - A. Matsuoka
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, Japan
| | - Y. Miyashita
- Korea Astronomy and Space Science Institute, Daejeon, South Korea
| | - Y. Miyoshi
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - I. Shinohara
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, Japan
| | - M. Teramoto
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | | | - A. J. Halford
- Space Sciences Department, The Aerospace Corporation, Chantilly, VA USA
| | - M. McCarthy
- Department of Earth and Space Sciences, University of Washington, Seattle, WA USA
| | - R. M. Millan
- Department of Physics and Astronomy, Dartmouth College, Hanover, NH USA
| | - J. G. Sample
- Department of Physics, Montana State University, Bozeman, MT USA
| | - D. M. Smith
- Santa Cruz Institute of Particle Physics and Department of Physics, University of California, Santa Cruz, CA 95064 USA
| | - L. A. Woodger
- Department of Physics and Astronomy, Dartmouth College, Hanover, NH USA
| | - A. Masson
- European Space Agency, ESAC, SCI-OPD, Madrid, Spain
| | - A. A. Narock
- ADNET Systems Inc., NASA Goddard Space Flight Center, Greenbelt, MD USA
| | - K. Asamura
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, Japan
| | - T. F. Chang
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - C.-Y. Chiang
- Institute of Space and Plasma Sciences, National Cheng Kung University, Tainan, Taiwan
| | - Y. Kazama
- Academia Sinica Institute of Astronomy and Astrophysics, Taipei, Taiwan
| | - K. Keika
- Department of Earth and Planetary Science, Graduate School of Science, University of Tokyo, Tokyo, Japan
| | - S. Matsuda
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - T. Segawa
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - K. Seki
- Department of Earth and Planetary Science, Graduate School of Science, University of Tokyo, Tokyo, Japan
| | - M. Shoji
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - S. W. Y. Tam
- Institute of Space and Plasma Sciences, National Cheng Kung University, Tainan, Taiwan
| | - N. Umemura
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - B.-J. Wang
- Academia Sinica Institute of Astronomy and Astrophysics, Taipei, Taiwan
- Graduate Institute of Space Science, National Central University, Taoyuan, Taiwan
| | - S.-Y. Wang
- Academia Sinica Institute of Astronomy and Astrophysics, Taipei, Taiwan
| | - R. Redmon
- National Centers for Environmental Information, National Oceanic and Atmospheric Administration, Boulder, CO USA
| | - J. V. Rodriguez
- National Centers for Environmental Information, National Oceanic and Atmospheric Administration, Boulder, CO USA
- Cooperative Institute for Research in Environmental Sciences (CIRES) at University of Colorado at Boulder, Boulder, CO USA
| | - H. J. Singer
- Space Weather Prediction Center, National Oceanic and Atmospheric Administration, Boulder, CO USA
| | - J. Vandegriff
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD USA
| | - S. Abe
- International Center for Space Weather Science and Education, Kyushu University, Fukuoka, Japan
| | - M. Nose
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
- World Data Center for Geomagnetism, Kyoto Data Analysis Center for Geomagnetism and Space Magnetism, Kyoto University, Kyoto, Japan
| | - A. Shinbori
- Institute for Space-Earth Environmental Research, Nagoya University, Nagoya, Japan
| | - Y.-M. Tanaka
- National Institute of Polar Research, Tokyo, Japan
| | - S. UeNo
- Hida Observatory, Kyoto University, Kyoto, Japan
| | - L. Andersson
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO USA
| | - P. Dunn
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - C. Fowler
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO USA
| | - J. S. Halekas
- Department of Physics and Astronomy, University of Iowa, Iowa City, IA USA
| | - T. Hara
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - Y. Harada
- Department of Geophysics, Kyoto University, Kyoto, Japan
| | - C. O. Lee
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - R. Lillis
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - D. L. Mitchell
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - M. R. Argall
- Physics Department and Space Science Center, University of New Hampshire, Durham, NH USA
| | - K. Bromund
- NASA Goddard Space Flight Center, Greenbelt, MD USA
| | - J. L. Burch
- Southwest Research Institute, San Antonio, TX USA
| | - I. J. Cohen
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD USA
| | - M. Galloy
- National Center for Atmospheric Research, Boulder, CO USA
| | - B. Giles
- NASA Goddard Space Flight Center, Greenbelt, MD USA
| | - A. N. Jaynes
- Department of Physics and Astronomy, University of Iowa, Iowa City, IA USA
| | - O. Le Contel
- Laboratoire de Physique des Plasmas, CNRS/Ecole Polytechnique/Sorbonne Université/Univ. Paris Sud/Observatoire de Paris, Paris, France
| | - M. Oka
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - T. D. Phan
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - B. M. Walsh
- Center for Space Physics, Department of Mechanical Engineering, Boston University, Boston, MA USA
| | - J. Westlake
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD USA
| | - F. D. Wilder
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO USA
| | - S. D. Bale
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - R. Livi
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - M. Pulupa
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - P. Whittlesey
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - A. DeWolfe
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO USA
| | - B. Harter
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO USA
| | - E. Lucas
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO USA
| | - U. Auster
- Institute for Geophysics and Extraterrestrial Physics, Technical University of Braunschweig, Braunschweig, Germany
| | - J. W. Bonnell
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - C. M. Cully
- University of Calgary, Calgary, Ontario Canada
| | - E. Donovan
- University of Calgary, Calgary, Ontario Canada
| | - R. E. Ergun
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO USA
| | - H. U. Frey
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - B. Jackel
- University of Calgary, Calgary, Ontario Canada
| | - A. Keiling
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - H. Korth
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD USA
| | - J. P. McFadden
- Space Sciences Laboratory, University of California, Berkeley, USA
| | - Y. Nishimura
- Center for Space Physics and Department of Electrical and Computer Engineering, Boston University, Boston, MA USA
| | - F. Plaschke
- Space Research Institute, Austrian Academy of Sciences, Institute of Physics, University of Graz, Graz, Austria
| | - P. Robert
- Laboratoire de Physique des Plasmas, CNRS/Ecole Polytechnique/Sorbonne Université/Univ. Paris Sud/Observatoire de Paris, Paris, France
| | | | - J. M. Weygand
- Department of Earth, Planetary and Space Sciences, and Institute of Geophysics and Planetary Physics, University of California, Los Angeles, USA
| | - R. M. Candey
- NASA Goddard Space Flight Center, Greenbelt, MD USA
| | - R. C. Johnson
- ADNET Systems Inc., NASA Goddard Space Flight Center, Greenbelt, MD USA
| | - T. Kovalick
- ADNET Systems Inc., NASA Goddard Space Flight Center, Greenbelt, MD USA
| | - M. H. Liu
- ADNET Systems Inc., NASA Goddard Space Flight Center, Greenbelt, MD USA
| | | | - A. Breneman
- University of Minnesota, Minneapolis, MN USA
| | - K. Kersten
- University of Minnesota, Minneapolis, MN USA
| | - P. Schroeder
- Space Sciences Laboratory, University of California, Berkeley, USA
| |
Collapse
|
22
|
Yasuno S, Miyoshi Y, Asano N, Okita T, Yamaguchi M, Shimomura N, Kashiwagi K, Shimomura Y. Sporadic case of Darier disease caused by a novel splice-site mutation in the ATP2A2 gene. Clin Exp Dermatol 2018; 44:e10-e12. [PMID: 30294936 DOI: 10.1111/ced.13806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/19/2018] [Indexed: 11/29/2022]
Affiliation(s)
- S Yasuno
- Department of Dermatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
| | - Y Miyoshi
- Department of Dermatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
| | - N Asano
- Department of Dermatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
| | - T Okita
- Department of Dermatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
| | - M Yamaguchi
- Department of Dermatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
| | - N Shimomura
- Department of Dermatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
| | - K Kashiwagi
- Department of Dermatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
| | - Y Shimomura
- Department of Dermatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
| |
Collapse
|
23
|
Kitamura N, Kitahara M, Shoji M, Miyoshi Y, Hasegawa H, Nakamura S, Katoh Y, Saito Y, Yokota S, Gershman DJ, Vinas AF, Giles BL, Moore TE, Paterson WR, Pollock CJ, Russell CT, Strangeway RJ, Fuselier SA, Burch JL. Direct measurements of two-way wave-particle energy transfer in a collisionless space plasma. Science 2018; 361:1000-1003. [PMID: 30190400 DOI: 10.1126/science.aap8730] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Accepted: 07/04/2018] [Indexed: 11/02/2022]
Abstract
Particle acceleration by plasma waves and spontaneous wave generation are fundamental energy and momentum exchange processes in collisionless plasmas. Such wave-particle interactions occur ubiquitously in space. We present ultrafast measurements in Earth's magnetosphere by the Magnetospheric Multiscale spacecraft that enabled quantitative evaluation of energy transfer in interactions associated with electromagnetic ion cyclotron waves. The observed ion distributions are not symmetric around the magnetic field direction but are in phase with the plasma wave fields. The wave-ion phase relations demonstrate that a cyclotron resonance transferred energy from hot protons to waves, which in turn nonresonantly accelerated cold He+ to energies up to ~2 kilo-electron volts. These observations provide direct quantitative evidence for collisionless energy transfer in plasmas between distinct particle populations via wave-particle interactions.
Collapse
Affiliation(s)
- N Kitamura
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, Japan. .,Department of Earth and Planetary Science, Graduate School of Science, the University of Tokyo, Tokyo, Japan
| | - M Kitahara
- Department of Geophysics, Graduate School of Science, Tohoku University, Sendai, Japan
| | - M Shoji
- Institute for Space-Earth Environmental Research (ISEE), Nagoya University, Nagoya, Japan
| | - Y Miyoshi
- Institute for Space-Earth Environmental Research (ISEE), Nagoya University, Nagoya, Japan
| | - H Hasegawa
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, Japan
| | - S Nakamura
- Research Institute for Sustainable Humanosphere (RISH), Kyoto University, Uji, Japan
| | - Y Katoh
- Department of Geophysics, Graduate School of Science, Tohoku University, Sendai, Japan
| | - Y Saito
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Sagamihara, Japan
| | - S Yokota
- Department of Earth and Space Science, Graduate School of Science, Osaka University, Toyonaka, Japan
| | - D J Gershman
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - A F Vinas
- NASA Goddard Space Flight Center, Greenbelt, MD, USA.,Department of Physics, American University, Washington, DC, USA
| | - B L Giles
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - T E Moore
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - W R Paterson
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | | | - C T Russell
- Institute of Geophysics and Planetary Physics, University of California, Los Angeles, CA, USA
| | - R J Strangeway
- Institute of Geophysics and Planetary Physics, University of California, Los Angeles, CA, USA
| | - S A Fuselier
- Southwest Research Institute, San Antonio, TX, USA.,University of Texas at San Antonio, San Antonio, TX, USA
| | - J L Burch
- Southwest Research Institute, San Antonio, TX, USA
| |
Collapse
|
24
|
Kondo M, Miyoshi Y, Tarumoto K, Hirayama N, Sasaki T, Yamashita K, Yamashita S, Hatao K. Severe and Recurrent Hypoglycemia Caused by Garenoxacin in a Patient not Taking Hypoglycemic Drugs. Intern Med 2018; 57:2041-2043. [PMID: 29491302 PMCID: PMC6096026 DOI: 10.2169/internalmedicine.0366-17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Quinolones are known to induce hypoglycemia, although there is no written report of garenoxacin-induced hypoglycemia. We herein report a case of garenoxacin-induced hypoglycemia in a patient not taking hypoglycemic drugs. An 89-year-old Japanese woman with type 2 diabetes and chronic renal insufficiency requiring hemodialysis was admitted to the emergency department in a comatose state. Her serum glucose measured 1 mg/dL on arrival. The patient had not taken any hypoglycemic drugs recently and had never experienced a hypoglycemic episode. She had received a four-day course of garenoxacin treatment before the emergency admission. Clinicians should therefore recognize the potential risk of hypoglycemia during garenoxacin therapy.
Collapse
Affiliation(s)
- Manabu Kondo
- Department of Endocrinology and Hematology, Tokuyama Central Hospital, Japan
| | - Yuka Miyoshi
- Department of Endocrinology and Hematology, Tokuyama Central Hospital, Japan
| | - Kohji Tarumoto
- Department of Emergency and Critical Care Medicine, Tokuyama Central Hospital, Japan
| | - Norie Hirayama
- Department of Pharmacy, Tokuyama Central Hospital, Japan
| | - Takahiro Sasaki
- Department of Endocrinology and Hematology, Tokuyama Central Hospital, Japan
| | - Kohji Yamashita
- Department of Endocrinology and Hematology, Tokuyama Central Hospital, Japan
| | - Susumu Yamashita
- Department of Emergency and Critical Care Medicine, Tokuyama Central Hospital, Japan
| | - Katsuhiro Hatao
- Department of Endocrinology and Hematology, Tokuyama Central Hospital, Japan
| |
Collapse
|
25
|
Kasahara S, Miyoshi Y, Yokota S, Mitani T, Kasahara Y, Matsuda S, Kumamoto A, Matsuoka A, Kazama Y, Frey HU, Angelopoulos V, Kurita S, Keika K, Seki K, Shinohara I. Pulsating aurora from electron scattering by chorus waves. Nature 2018; 554:337-340. [PMID: 29446380 DOI: 10.1038/nature25505] [Citation(s) in RCA: 111] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Accepted: 12/21/2017] [Indexed: 11/09/2022]
Abstract
Auroral substorms, dynamic phenomena that occur in the upper atmosphere at night, are caused by global reconfiguration of the magnetosphere, which releases stored solar wind energy. These storms are characterized by auroral brightening from dusk to midnight, followed by violent motions of distinct auroral arcs that suddenly break up, and the subsequent emergence of diffuse, pulsating auroral patches at dawn. Pulsating aurorae, which are quasiperiodic, blinking patches of light tens to hundreds of kilometres across, appear at altitudes of about 100 kilometres in the high-latitude regions of both hemispheres, and multiple patches often cover the entire sky. This auroral pulsation, with periods of several to tens of seconds, is generated by the intermittent precipitation of energetic electrons (several to tens of kiloelectronvolts) arriving from the magnetosphere and colliding with the atoms and molecules of the upper atmosphere. A possible cause of this precipitation is the interaction between magnetospheric electrons and electromagnetic waves called whistler-mode chorus waves. However, no direct observational evidence of this interaction has been obtained so far. Here we report that energetic electrons are scattered by chorus waves, resulting in their precipitation. Our observations were made in March 2017 with a magnetospheric spacecraft equipped with a high-angular-resolution electron sensor and electromagnetic field instruments. The measured quasiperiodic precipitating electron flux was sufficiently intense to generate a pulsating aurora, which was indeed simultaneously observed by a ground auroral imager.
Collapse
Affiliation(s)
- S Kasahara
- Department of Earth and Planetary Science, School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - Y Miyoshi
- Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, 24105 Nagoya, Aichi, Japan
| | - S Yokota
- Department of Earth and Space Science, Graduate School of Science, Osaka University, 1-1 Machikaneyama-cho, Toyonaka, Osaka, Japan
| | - T Mitani
- Institute of Space and Astronautical Science, 3-1-1 Yoshinodai, Chuo-ku, Sagamihara, Kanagawa, Japan
| | - Y Kasahara
- Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa, Japan
| | - S Matsuda
- Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, 24105 Nagoya, Aichi, Japan
| | - A Kumamoto
- Graduate School of Science, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai 980-8578 Japan
| | - A Matsuoka
- Institute of Space and Astronautical Science, 3-1-1 Yoshinodai, Chuo-ku, Sagamihara, Kanagawa, Japan
| | - Y Kazama
- Academia Sinica Institute of Astronomy and Astrophysics, 11F Astronomy-Mathematics Building, AS/NTU, No. 1, Sec. 4, Roosevelt Road, Taipei 10617, Taiwan
| | - H U Frey
- Space Sciences Laboratory, University of California, Berkeley, California 94720-7450, USA
| | - V Angelopoulos
- Department of Earth, Planetary and Space Sciences, University of California, Los Angeles, California 90095-1567, USA
| | - S Kurita
- Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa-ku, 24105 Nagoya, Aichi, Japan
| | - K Keika
- Department of Earth and Planetary Science, School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - K Seki
- Department of Earth and Planetary Science, School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - I Shinohara
- Institute of Space and Astronautical Science, 3-1-1 Yoshinodai, Chuo-ku, Sagamihara, Kanagawa, Japan
| |
Collapse
|
26
|
Ohi T, Komiyama T, Miyoshi Y, Murakami T, Tsuboi A, Tomata Y, Tsuji I, Watanabe M, Hattori Y. Maximum Occlusal Force and Incident Functional Disability in Older Adults: The Tsurugaya Project. JDR Clin Trans Res 2018; 3:195-202. [DOI: 10.1177/2380084418761329] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Affiliation(s)
- T. Ohi
- Division of Aging and Geriatric Dentistry, Department of Oral Function and Morphology, Tohoku University Graduate School of Dentistry, Sendai, Japan
- Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Japan
| | - T. Komiyama
- Division of Aging and Geriatric Dentistry, Department of Oral Function and Morphology, Tohoku University Graduate School of Dentistry, Sendai, Japan
| | - Y. Miyoshi
- Division of Aging and Geriatric Dentistry, Department of Oral Function and Morphology, Tohoku University Graduate School of Dentistry, Sendai, Japan
| | - T. Murakami
- Division of Public Health, Hygiene and Epidemiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
| | - A. Tsuboi
- Department of Community Medical Supports, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan
| | - Y. Tomata
- Division of Epidemiology, Department of Health Informatics and Public Health, Tohoku University School of Public Health, Graduate School of Medicine, Sendai, Japan
| | - I. Tsuji
- Division of Epidemiology, Department of Health Informatics and Public Health, Tohoku University School of Public Health, Graduate School of Medicine, Sendai, Japan
| | - M. Watanabe
- Department of Social Welfare, Faculty of General Welfare, Tohoku Fukushi University, Sendai, Japan
| | - Y. Hattori
- Division of Aging and Geriatric Dentistry, Department of Oral Function and Morphology, Tohoku University Graduate School of Dentistry, Sendai, Japan
| |
Collapse
|
27
|
Araki K, Ito Y, Fukada I, Kobayashi K, Ohno S, Miyagawa Y, Imamura M, Kira A, Takatsuka Y, Egawa C, Suwa H, Miyoshi Y. Abstract P2-09-31: Predictive impact of absolute lymphocyte counts for progression-free survival in HER2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-09-31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor-infiltrating lymphocytes might be a one of predictive outcome of human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC) patients (pts) who treated with trastuzumab and pertuzumab (TP) plus docetaxel. Although peripheral blood-based parameter (PBBP) is reported as a prognostic indicator of patients with early breast cancers, utility of PBBP has not been studied in HER2-positive ABC.
Objective:The aim of our study was to determine whether PBBP is significant for predictive efficacy in HER2-positive ABC treated with TP combined with eribulin (ERI) or nab-paclitaxel (Nab-PTX).
Methods: The 51 patients' data from two single arm phase II trials was included in this retrospective-prospective study; ERI + TP (n=30) or Nab-PTX + TP (n=21) registered with UMIN000012375 or UMIN000006838, respectively. We assessed the PBBP in prospectively collected data and investigated their association with progression-free survival (PFS). In consideration of PBBP, we evaluated absolute lymphocyte count (ALC), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR). The cutoff values of ALC, NLR, and PLR were set at 1000 cells/μL, 2, and 250, respectively.
Results:Median age at baseline was 58 years (range: 31-77). Median number of previous chemotherapy was 3 (range: 1-10). Pts had multiple metastases, 53% with LNs, 35% with bone, 25% with lung, 20% with liver, and 6% with brain. The objective response rate (CR+PR) and clinical benefit rate (CR+PR+ more than 6 month SD) were 37% (n=19) and 59% (n=30), respectively. The median PFS of all pts was 301 days (range: 21-1281). The PFS of pts with ALC-High was significantly better than those of ALC-low (hazard ratio (HR): 2.74, 95% confidence interval (CI): 1.28 to 5.86; p= .0097). Furthermore, improved PFS was obtained in pts with ALC greater than 1500 cells/μL compared with less than 1000 cells/uL (HR: 4.05, 95% CI: 1.60 to 11.6; p= .0029). Significant associations seem to exist irrespective of number of previous chemotherapy. Since we combined different studies for evaluating PBBP, ERI and Nab-PTX were calculated separately. Marginally significant associations between ALC and PFS were obtained both in ERI (HR: 2.18, 95% CI: 0.87 to 5.60; p=.0973) and Nab-PTX (HR: 3.26, 95% CI: 0.80 to 12.4; p=.0939). The PFS of NLR-low pts was significantly better than those of NLR-high (HR: 2.29, 95% CI: 1.01 to 5.90; p= .0477), but this statistical difference was inferior to those of ALC. There was no significant association between PLR and PFS.
Conclusions: Pre-treatment ALC-High was significantly correlated with favorable PFS of pts treated with TP irrespective of combination chemotherapy in HER2-positve ABC. Prolonged PFS of TP combination therapy might be obtained mediating through host systemic onco-immunity. These data obtained here suggest that a usefulness of ALC for selecting pts who might have clinical benefit from TP combination therapy for heavily treated HER2-positve ABC.
Citation Format: Araki K, Ito Y, Fukada I, Kobayashi K, Ohno S, Miyagawa Y, Imamura M, Kira A, Takatsuka Y, Egawa C, Suwa H, Miyoshi Y. Predictive impact of absolute lymphocyte counts for progression-free survival in HER2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-09-31.
Collapse
Affiliation(s)
- K Araki
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - Y Ito
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - I Fukada
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - K Kobayashi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - S Ohno
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - Y Miyagawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - M Imamura
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - A Kira
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - Y Takatsuka
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - C Egawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - H Suwa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - Y Miyoshi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute of the Japanese Foundation for Cancer Research Japan, Koto, Tokyo, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| |
Collapse
|
28
|
Hayasaka N, Hirano A, Miyoshi Y, Tokuda IT, Yoshitane H, Matsuda J, Fukada Y. Salt-inducible kinase 3 regulates the mammalian circadian clock by destabilizing PER2 protein. eLife 2017; 6:24779. [PMID: 29227248 PMCID: PMC5747517 DOI: 10.7554/elife.24779] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2017] [Accepted: 12/08/2017] [Indexed: 01/07/2023] Open
Abstract
Salt-inducible kinase 3 (SIK3) plays a crucial role in various aspects of metabolism. In the course of investigating metabolic defects in Sik3-deficient mice (Sik3-/-), we observed that circadian rhythmicity of the metabolisms was phase-delayed. Sik3-/- mice also exhibited other circadian abnormalities, including lengthening of the period, impaired entrainment to the light-dark cycle, phase variation in locomotor activities, and aberrant physiological rhythms. Ex vivo suprachiasmatic nucleus slices from Sik3-/- mice exhibited destabilized and desynchronized molecular rhythms among individual neurons. In cultured cells, Sik3-knockdown resulted in abnormal bioluminescence rhythms. Expression levels of PER2, a clock protein, were elevated in Sik3-knockdown cells but down-regulated in Sik3-overexpressing cells, which could be attributed to a phosphorylation-dependent decrease in PER2 protein stability. This was further confirmed by PER2 accumulation in the Sik3-/- fibroblasts and liver. Collectively, SIK3 plays key roles in circadian rhythms by facilitating phosphorylation-dependent PER2 destabilization, either directly or indirectly.
Collapse
Affiliation(s)
- Naoto Hayasaka
- Department of Neuroscience II, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.,PRESTO, Japan Science and Technology Agency, Kawaguchi, Japan.,Department of Anatomy and Neurobiology, Kindai University Faculty of Medicine, Osaka, Japan
| | - Arisa Hirano
- Department of Biological Sciences, School of Science, The University of Tokyo, Tokyo, Japan
| | - Yuka Miyoshi
- Department of Anatomy and Neurobiology, Kindai University Faculty of Medicine, Osaka, Japan
| | - Isao T Tokuda
- Department of Mechanical Engineering, Ritsumeikan University, Kusatsu, Japan
| | - Hikari Yoshitane
- Department of Biological Sciences, School of Science, The University of Tokyo, Tokyo, Japan
| | - Junichiro Matsuda
- Laboratory of Animal Models for Human Diseases, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan
| | - Yoshitaka Fukada
- Department of Biological Sciences, School of Science, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
29
|
Hattori M, Tamura K, Mukai H, Miyoshi Y, Masuda N, Suzuki E, Ishiguro H, Ohtani S, Hara F, Shimamoto T, Yamamoto K, Ding Y, Aktan G, Karantza V, Iwata H. Phase 2 study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC): Japanese subgroup results of KEYNOTE 086. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx654.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Miyoshi Y, Suzuki E, Kiyoto S, Takahashi M, Takashima S, Hara F, Aogi K, Shozo O. Reproductive factors and Breast cancer subtypes among Japanese women. Breast 2017. [DOI: 10.1016/s0960-9776(17)30200-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
31
|
|
32
|
Kawada K, Taira N, Hatono M, Takahashi Y, Miyoshi Y, Nogami T, Iwamoto T, Motoki T, Sien T, Matsuoka J, Doihara H, Ikeda M, Ogasawara Y, Takabatake D, Yoshitomi S, Kiyoto S, Yamamoto S, Mizota Y, Oka K. Abstract OT3-07-02: Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot3-07-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
[Background]
Past studies revealed that a moderate to high level of physical activity after diagnosis of breast cancer reduces both the risk of breast cancer-related death and death from all causes. Furthermore, some randomized studies suggested that exercise programs improve the percentage of patients who complete the chemotherapy and quality of life, and decrease fatigue, and adverse events. The issues to be determined include defining an established uniform exercise program and the efficacy of a long-term exercise program after breast cancer surgery.
[Object] To elucidate the efficacy of a long-term exercise program and to verify the safety and feasibility of a uniform exercise program using an ‘existing social resource’ after primary therapy of breast cancer.
[Design] A multi-center, randomized trial.
[Method] Subjects: The subjects included patients who had completed treatment for primary breast cancer, including surgery and/or adjuvant chemotherapy. Patients with metastatic breast cancer were excluded.
Randomization & intervention: The patients were randomly assigned to three groups.
The first group followed an exercise program at Curves® that involved 30 minutes of exercise, including aerobics, weight training, and stretching 3 times a week for 4 months. The second group was given life-style guidance at least once that patients participate in a lecture program about recommended exercise at this point and the importance of weight control after diagnosis of breast cancer using a brochure. The third group served as controls that the patients receive a brochure used same one in the second group. The variables included age and weight.
Outcome: The primary endpoint is level of physical activity at 1 year after randomization, and the secondary endpoints are the percentage of those completing the exercise program, patient reported outcomes (QOL, cancer or treatment associated symptoms, fatigue, depression, and anxiety), body mass index, bone density, and level of lymphedema.
Period of research: The study will last 2 years beginning March 2016.
Sample size: We plan to enroll 400 patients to detect 20% difference with 90% power.
Additional study: Some biochemical markers in the blood will be evaluated to determine the mechanism of the effect of exercise on the human body.
Citation Format: Kawada K, Taira N, Hatono M, Takahashi Y, Miyoshi Y, Nogami T, Iwamoto T, Motoki T, Sien T, Matsuoka J, Doihara H, Ikeda M, Ogasawara Y, Takabatake D, Yoshitomi S, Kiyoto S, Yamamoto S, Mizota Y, Oka K. Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-07-02.
Collapse
Affiliation(s)
- K Kawada
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - N Taira
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - M Hatono
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - Y Takahashi
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - Y Miyoshi
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - T Nogami
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - T Iwamoto
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - T Motoki
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - T Sien
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - J Matsuoka
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - H Doihara
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - M Ikeda
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - Y Ogasawara
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - D Takabatake
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - S Yoshitomi
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - S Kiyoto
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - S Yamamoto
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - Y Mizota
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| | - K Oka
- Okayama University Hospital, Okayama, Japan; Fukuyama City Hospital, Fukuyama, Hiroshima, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan; Kochi Health Science Center, Kochi, Japan; Japanese Red Cross Okayama Hospital, Okayama, Japan; Shikoku Cancer Center, Matsumoto, Ehime, Japan; Nashonal Cancer Center Hospital, Chuo-ku, Tokyo, Japan; Faculty of Sport Sciences, Waseda University, Shinjuku-ku, Tokyo, Japan
| |
Collapse
|
33
|
Fujimoto Y, Imamura M, Higuchi T, Nishimukai A, Yanai A, Miyagawa Y, Murase K, Takatsuka Y, Miyoshi Y. Abstract P2-05-27: Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-05-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: It has been well demonstrated that patients who achieved pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) had a favorable prognosis compared with patients who did not (non-pCR). Even though pCR was not attained, reduction in tumor volume after chemotherapy may be associated with improved prognosis for a certain number of patients. However, the association between residual tumor volume and prognosis is not necessarily consistent. In order to identify substitute markers for breast cancer patients with non-pCR after NAC, we investigated the impact of serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA15-3) at baseline as well as post-NAC.
Patients and Methods: Ninety-six breast cancer patients treated with NAC and operated on at the Hyogo College of Medicine were recruited for this study. Serum CEA and CA15-3 were measured prior to chemotherapy as well as at completion of pre-operative treatment. The optimal cutoff points for CEA (1.55ng/m, normal range: <5.0ng/ml) and CA15-3 (13.25U/ml, normal range: <28.0U/ml) for relapse-free survival (RFS) were determined by analyzing the area under receiver operating characteristic curves in another study involving 613 breast cancer patients. Expression levels of Ki67 in samples obtained at pre- and post-NAC were also determined by means of immunohistochemical staining. Pathological complete response was classified as the absence of residual invasive cancer in the breast and lymph nodes. During a 2.13 years median follow-up period, 15 patients suffered relapse.
Results: pCR and non-pCR was attained by 21 and 75 patients, respectively. For the non-pCR patients, serum CEA levels at baseline were classified into high (n=35) and low (n=38) and serum CA15-3 levels at baseline into high (n=31) and low (n=43). RFS of non-pCR patients with high serum CA15-3 levels was significantly worse than of those with low levels (3-year RFS: 0.47 vs 0.93; p=0.0009). RFS for patients with high and low serum levels of CA15-3 after NAC was also significantly different (p=0.037). As for CEA, no significant association with RFS was observed either at baseline or post-NAC. Univariate analysis demonstrated that tumor size and baseline CA15-3 were significant prognostic factors for RFS. Multivariate analysis showed that both tumor size (hazard ratio (HR): 3.88, 95% confidence interval (CI): 1.21-12.35, p=0.023) and baseline CA15-3 (HR: 13.51, 95% CI: 1.74-105.08, p=0.013) were significant and independent risk factors for relapse. As for lymph node metastasis, tumor grade, residual tumor size and pre- and post-NAC Ki67 expression levels of patients with non-pCR showed no significant association with RFS.
Conclusion and discussion: High levels of serum CA15-3 at baseline constituted a significantly worse prognosis for breast cancer patients with non-pCR. Tumor size at baseline but not residual size and baseline CA15-3 seems to suitable as a substitute for prediction of outcome for patients with non-pCR. Our findings suggest that these markers may be useful for identifying patients with poor prognosis who may be candidates for additional adjuvant treatment.
Citation Format: Fujimoto Y, Imamura M, Higuchi T, Nishimukai A, Yanai A, Miyagawa Y, Murase K, Takatsuka Y, Miyoshi Y. Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-05-27.
Collapse
Affiliation(s)
- Y Fujimoto
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - M Imamura
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - T Higuchi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - A Nishimukai
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - A Yanai
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Miyagawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - K Murase
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Takatsuka
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Miyoshi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| |
Collapse
|
34
|
Miyoshi Y, Uemura H, Suzuki K, Shibata Y, Honma S, Harada M, Kubota Y. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL. Andrology 2016; 5:262-267. [PMID: 27813361 DOI: 10.1111/andr.12294] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Revised: 09/03/2016] [Accepted: 09/12/2016] [Indexed: 11/30/2022]
Abstract
There has been no consensus on the role of serum androgen concentrations in prostate cancer detection in men with prostate-specific antigen levels of 3-10 ng/mL. In this study, testosterone and dihydrotestosterone concentrations in blood were examined by a newly developed method using ultrasensitive liquid chromatography with two serially linked mass spectrometers (LC-MS/MS). We investigated the correlation between serum androgen levels and Gleason scores at biopsy. We analyzed data of 157 men with a total prostate-specific antigen range of 3-10 ng/mL who underwent initial systematic prostate needle biopsy for suspected prostate cancer between April 2000 and July 2003. Peripheral blood testosterone and dihydrotestosterone concentrations were determined by LC-MS/MS. Blood levels of testosterone and dihydrotestosterone were compared with pathological findings by multivariate analyses. Median values of prostate-specific antigen and prostate volume measured by ultrasound were 5.7 ng/mL and 31.4 cm3 , respectively. Benign prostatic hyperplasia was diagnosed in 97 patients (61.8%), and prostate cancer was diagnosed in 60 (38.2%) patients, including 31 (19.7%) patients with a Gleason score of 6 and 29 (18.5%) patients with a Gleason score of 7-10. Median values of testosterone and dihydrotestosterone in blood were 3798.7 and 371.7 pg/mL, respectively. There was a strong correlation between serum testosterone and dihydrotestosterone. In multivariate analysis, age, prostate volume, and serum dihydrotestosterone were significant predictors of benign prostatic hyperplasia or prostate cancer with a Gleason score of 6. The area under the receiver operating characteristics curve for age, prostate volume, and serum dihydrotestosterone were 0.67, 0.67, and 0.67, respectively . We confirmed that high dihydrotestosterone blood levels can predict benign prostatic hyperplasia or prostate cancer with a Gleason score of 6 in men with prostate-specific antigen levels of 3-10 ng/mL.
Collapse
Affiliation(s)
- Y Miyoshi
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.,Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
| | - H Uemura
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.,Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
| | - K Suzuki
- Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Y Shibata
- Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - S Honma
- ASKA Pharma Medical Co. Ltd., Kawasaki, Japan
| | - M Harada
- Department of Urology and Pathology, Kanagawa Cancer Center, Yokohama, Japan
| | - Y Kubota
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| |
Collapse
|
35
|
Miyoshi Y, Tanabe S, Suzuki T. Cellular zinc is required for intestinal epithelial barrier maintenance via the regulation of claudin-3 and occludin expression. Am J Physiol Gastrointest Liver Physiol 2016; 311:G105-16. [PMID: 27151944 DOI: 10.1152/ajpgi.00405.2015] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Accepted: 05/02/2016] [Indexed: 01/31/2023]
Abstract
Intracellular zinc is required for a variety of cell functions, but its precise roles in the maintenance of the intestinal tight junction (TJ) barrier remain unclear. The present study investigated the essential roles of intracellular zinc in the preservation of intestinal TJ integrity and the underlying molecular mechanisms. Depletion of intracellular zinc in both intestinal Caco-2 cells and mouse colons through the application of a cell-permeable zinc chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) induced a disruption of the TJ barrier, as indicated by increased FITC-labeled dextran flux and decreased transepithelial electrical resistance. The TPEN-induced TJ disruption is associated with downregulation of two TJ proteins, occludin and claudin-3. Biotinylation of cell surface proteins revealed that the zinc depletion induced the proteolysis of occludin but not claudin-3. Occludin proteolysis was sensitive to the inhibition of calpain activity, and increased calpain activity was observed in the zinc-depleted cells. Although quantitative PCR analysis and promoter reporter assay have demonstrated that the zinc depletion-induced claudin-3 downregulation occurred at transcriptional levels, a site-directed mutation in the egr1 binding site in the claudin-3 promoter sequence induced loss of both the basal promoter activity and the TPEN-induced decreases. Reduced egr1 expression by a specific siRNA also inhibited claudin-3 expression and transepithelial electrical resistance maintenance in cells. This study shows that intracellular zinc has an essential role in the maintenance of the intestinal epithelial TJ barrier through regulation of occludin proteolysis and claudin-3 transcription.
Collapse
Affiliation(s)
- Yuka Miyoshi
- Department of Biofunctional Science and Technology, Graduate School of Biosphere Science, Hiroshima University, Higashi-Hiroshima, Japan
| | - Soichi Tanabe
- Department of Biofunctional Science and Technology, Graduate School of Biosphere Science, Hiroshima University, Higashi-Hiroshima, Japan
| | - Takuya Suzuki
- Department of Biofunctional Science and Technology, Graduate School of Biosphere Science, Hiroshima University, Higashi-Hiroshima, Japan
| |
Collapse
|
36
|
Abstract
Programmed cell death-1 (PD-1), an immunoreceptor, is located on T cells and pro-B cells and interacts with its ligands to inhibit T cell activation and proliferation, thereby promoting immunological self-tolerance. Nivolumab, an anti-PD1 antibody, blocks PD-1 and can restore anticancer immune responses by abrogating PD-1 pathway-mediated T-cell inhibition. Autoimmune adverse events are expected with PD-1 therapy. Fulminant type 1 diabetes is the subtype of type 1 diabetes. The clinical feature is the extremely rapid progression of hyperglycemia and ketoacidosis. Here we describe a 66-year-old woman with advanced melanoma who was treated with nivolumab. After 4 months and six doses of the medicine, the patient was admitted to the hospital with complaints of nausea and vomiting. The laboratory data showed ketonuria, hyperglycemia (531 mg/dl), high anion gap metabolic acidosis, HbA1c (7.3%), and absence of insulin-secreting capacity. These data are compatible with the criteria of fulminant type 1 diabetes. The patient was diagnosed with diabetic ketoacidosis because of fulminant type 1 diabetes. The findings of this case indicated that nivolumab can cause fulminant type 1 diabetes. Diabetic ketoacidosis due to fulminant type 1 diabetes is potentially fatal condition. Thus, diabetic ketoacidosis due to fulminant type 1 diabetes should be considered in the differential diagnosis when patients treated with nivolumab complain of gastrointestinal symptoms.
Collapse
Affiliation(s)
- Yuka Miyoshi
- Department of Diabetes and Endocrinology, Kameda Medical Center
| | | | | |
Collapse
|
37
|
Miyoshi Y, Shien T, Ogiya A, Ishida N, Yamazaki K, Horii R, Horimoto Y, Masuda N, Yasojima H, Inao T, Osako T, Takahashi M, Tomioka N, Hagio K, Endo Y, Hosoda M, Yamashita H. Abstract P5-08-15: Prognostic value of aldehyde dehydrogenase 1 (ALDH1) and tumor infiltrating lymphocytes (TIL) to predict the late recurrence in ER positive, HER2 negative breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-08-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Aldehyde dehydrogenase 1(ALDH1) is known to be cancer stem cell marker. Also, tumor infiltrating lymphocytes (TILs) are known to be prognostic factor for triple negative breast cancer. It is reported that these factors have the correlation with chemosensitivity. Meanwhile, the late recurrence (LRec; 5 years after primary surgery) of ER positive breast cancer is the major problem. Significance of expressions of ALDH1 and TILs in primary tumor as predictive factors for late recurrence in ER positive, HER2 negative breast cancer is still unknown.
Methods: ER-positive, and HER2-negative breast cancer patients who underwent surgery or received neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutes belonging the Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. For each LRec patient, approximately two matched control patients without relapse for more than ten years were selected. Expression of ALDH1 was assessed by immunohistochemistry. Positive ALDH1 was defined as tumor including more than 1% cancer cells with ALDH1 expression. TIL was assessed by single whole section according to Denkert's definition. A tumor showing high ki67 and/or low PgR expressions was categorized into Luminal B-like group.
Results: 639 patients (184 with early recurrence (ERec), 134 with LRec and 321 with no recurrence (NoRec)) were analyzed. The rates of positive ALDH1 in ERec, LRec and NoRec groups were 18%, 13% and 8%, respectively. ALDH1 positivity was significantly higher in ERec compared with NoRec group (p<0.01). There was no significant difference between LRec and NoRec group (p=0.12). Positive ALDH1 showed significantly shorter DFS and OS in multivariate analyses (DFS: p=0.03, OS: p<0.01). Especially, that was the significantly prognostic factor in the Luminal B like tumor with adjuvant or neoadjuvant chemotherapy (p=0.01), but not in those without any chemotherapy (p=0.53). High TILs in ERec, LRec and NoRec was 1.1%, 1.5% and 3.7%, respectively. There was no significant difference among three recurrent groups (p=0.13). High TILs was not significantly associated with DFS (p=0.09) and OS (p=0.72). However, there was significant correlation between High TILs and DFS in Luminal B like group (p=0.04) and ALDH1-negative group (p=0.02).
Conclusion: In ER-positive, and HER2-negative breast cancer, ALDH1 was an independent prognostic factor (a predictor of ERec, but not LRec). ALDH1 might be a predictor of benefit from chemotherapy in Luminal B like subtype. TILs was neither a predictor of ERec nor LRec. However, significance of TILs as prognostic factor might differ depending on subtypes and cancer stemness.
Citation Format: Miyoshi Y, Shien T, Ogiya A, Ishida N, Yamazaki K, Horii R, Horimoto Y, Masuda N, Yasojima H, Inao T, Osako T, Takahashi M, Tomioka N, Hagio K, Endo Y, Hosoda M, Yamashita H. Prognostic value of aldehyde dehydrogenase 1 (ALDH1) and tumor infiltrating lymphocytes (TIL) to predict the late recurrence in ER positive, HER2 negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-08-15.
Collapse
Affiliation(s)
- Y Miyoshi
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - T Shien
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - A Ogiya
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - N Ishida
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - K Yamazaki
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - R Horii
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - Y Horimoto
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - N Masuda
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - H Yasojima
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - T Inao
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - T Osako
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - M Takahashi
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - N Tomioka
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - K Hagio
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - Y Endo
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - M Hosoda
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| | - H Yamashita
- Okayama University Hospital; Cancer Institute Hospital, Japanese Foundation for Cancer Research; Hokkaido University Hospital; Juntendo University School of Medicine; NHO Osaka National Hospital; Graduate School of Medical Science Kumamoto University; Kumamoto City Hospital; NHO Hokkaido Cancer Center; Nagoya City University Graduate School of Medical Sciences
| |
Collapse
|
38
|
Shimoda M, Nishimukai A, Shibata N, Kikuchi W, Hutawatari H, Ishihara H, Miyoshi Y, Noguchi S. Abstract P2-08-27: Prediction of bone metastases of breast cancer using combined markers of bone metabolism and inflammation. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-08-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Luminal breast cancer patients show a relatively favorable prognosis when treated with adjuvant hormonal therapy alone. However, some of these patients develop recurrence and they might derive benefit from adjuvant chemotherapy. Although several genomic profilings successfully developed to decide whether to administer adjuvant chemotherapy, clinically practical prediction methods of recurrence sites do not exist. Our previous study showed a possible prediction of bone metastases by using two serum markers; TRACP-5b as a marker of bone metabolism; likelihood of bone metastases, and CRP as a marker of inflammation; likelihood of distant recurrence. The incidence of bone metastases was significantly higher in high risk patients(+/+) than in the others(odds ratio: 10.9, P=0.040). In this study, we examined the potential of the two-marker prediction in the newly enrolled luminal patients.
Patients and methods
One hundred sixty luminal patients who underwent surgery were enrolled in this study. Their serum levels of TRACP-5b and CRP were measured in a blinded manner at the R & D laboratory of Nittobo Medical Co., Ltd. In the preliminary study, we identified that the median value of TRACP-5b in the premenopausal patients was lower than in the postmenopausal patients. We adjusted the value of TRACP-5b in the premenopausal patients and the cutoff value of TRACP-5b from 334 to 396mU/dL. The cutoff value of CRP was same as previous study(0.016 mg/dL). The odds ratio between +/+ and the others were calculated using MedCalc statistical software.
Results
One hundred sixty patients stratified into four classes according to the value of TRACP-5b and CRP: +/+ (n=43), +/- (n=38), -/+ (n=42) and -/- (n=37). Six of the 160 patients developed bone metastases as the initial site of replase within five years from surgery. The Incidence of bone metastases was 9.3%(4/43) in the +/+ patients and 1.7%(2/117) in the others. The incidence was significantly higher in the +/+ patients than in the others(odds ratio: 5.9, 95% CI 1.31 to 33.46, p= 0.045). When the other relapses than bone metastases were included in the analysis, no significant difference was observed between the two groups (odds ratio: 0.4, 95% CI 0.02 to 7.43, P=0.521). TRACP-5b concentration alone could not classify the patients into two groups according to significantly different incidences of bone metastases(odds ratio: 13.7, 95% CI 0.76 to 247.22, P=0.076).
Conclusion
The results in here show that the prediction of bone metastases by the combination of TRACP-5b and CRP concentrations is clinically relevant in the luminal patients. Reliable prediction of bone metastases would be realized by combination of our prediction method and one of genomic profilings. We plan to increase the number of patients to provide sufficient statistical power to confirm this diagnostic potential.
Citation Format: Shimoda M, Nishimukai A, Shibata N, Kikuchi W, Hutawatari H, Ishihara H, Miyoshi Y, Noguchi S. Prediction of bone metastases of breast cancer using combined markers of bone metabolism and inflammation. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-08-27.
Collapse
Affiliation(s)
- M Shimoda
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nittobo Medical Co., Ltd, Koriyama, Fukushima, Japan
| | - A Nishimukai
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nittobo Medical Co., Ltd, Koriyama, Fukushima, Japan
| | - N Shibata
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nittobo Medical Co., Ltd, Koriyama, Fukushima, Japan
| | - W Kikuchi
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nittobo Medical Co., Ltd, Koriyama, Fukushima, Japan
| | - H Hutawatari
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nittobo Medical Co., Ltd, Koriyama, Fukushima, Japan
| | - H Ishihara
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nittobo Medical Co., Ltd, Koriyama, Fukushima, Japan
| | - Y Miyoshi
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nittobo Medical Co., Ltd, Koriyama, Fukushima, Japan
| | - S Noguchi
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Nittobo Medical Co., Ltd, Koriyama, Fukushima, Japan
| |
Collapse
|
39
|
Imamura M, Nishimikai A, Yanai A, Miyagawa Y, Higuchi T, Ozawa H, Murase K, Takatsuka Y, Miyoshi Y. Abstract P2-08-24: High levels of serum C-terminal crosslinking telopeptide of type 1 collagen at baseline are associated with poor prognosis for breast cancer patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-08-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: It has been demonstrated that adjuvant treatment using bisphosphonate may reduce recurrence among breast cancer patients. However, these improved prognoses of patients are reportedly limited to breast cancers of estrogen receptor (ER)-positive and postmenopausal women. Although the mechanisms of the effects of bisphosphonate remain unknown, this finding seems to represent support for the hypothesis that suppression of bone resorption by bisphosphonate results in favorable prognoses at least for patients in this subset. In order to determine the prognostic significance of bone resorption in breast cancer patients, we investigated these markers c-terminal crosslinking telopeptide of type I collagen (1CTP) and N-telopeptide of type I collagen (NTX).
Patients and Methods: 469 breast cancer patients were recruited who were operated on Hyogo College of Medicine and histologically confirmed to have invasive carcinoma. Serum 1CTP and NTX were measured preoperatively with the two-antibody radioimmunoassay and enzyme-linked immunosorbent assay methods, respectively, and blood samples were obtained before treatment from patients who were treated with neoadjuvant chemotherapy or endocrine therapy. The area under receiver operating characteristic curves were applied and optimal cutoff values were set at 3.6ng/ml for 1CTP, and 10.55nmolBCE/L premenopausal and 14.05nmolBCE/L postmenopausal for NTX. The relationships between these bone turnover markers and various clinicopathological characteristics were evaluated with the chi square or Fisher's exact test. The log-rank test was used to compare relapse-free survival (RFS) in Kaplan-Meier plots. Associations of RFS were assessed with a Cox proportional-hazards model based on the results of univariate and multivariate analyses. Differences were considered statistically significant if p<0.05.
Results: There were significantly more 1CTP-high patients among postmenopausal women and RFS of 1CTP-high patients was significantly worse than that of 1CTP-low patients (5-year RFS: 0.65 vs 0.86; p=0.0002). Similarly, NTX-high patients were significantly associated with postmenopausal status, but there was no significant association between NTX-high worse RFS (p=0.0976). Multivariate analysis of tumor size, lymph node metastasis and nuclear grade identified 1CTP (hazard ratio: 2.04, 95% confidence interval: 1.13-3.68; p=0.018) as a significant independent prognostic factor. Subset analyses of 1CTP showed that prognosis was consistently worse recognized for postmenopausal (p=0.0002), but not premenopausal (p=0.37) patients. Furthermore, prognosis for 1CTP-high patients was worse for the estrogen receptor (ER)-positive subset (p=0.0005) but not for the ER-negative subset (p=0.22).
Conclusion and discussion: High levels of serum bone resorption markers at baseline were identified as significant unfavorable prognostic factors for breast cancer patients. The prognostic significance of 1CTP seems to be prominent for postmenopausal patients with ER-positive breast cancers. These findings suggest the use of bone-modifying agents as an adjuvant therapy may be beneficial for breast cancer patients, especially for patients with high serum levels of 1CTP.
Citation Format: Imamura M, Nishimikai A, Yanai A, Miyagawa Y, Higuchi T, Ozawa H, Murase K, Takatsuka Y, Miyoshi Y. High levels of serum C-terminal crosslinking telopeptide of type 1 collagen at baseline are associated with poor prognosis for breast cancer patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-08-24.
Collapse
Affiliation(s)
- M Imamura
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - A Nishimikai
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - A Yanai
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Miyagawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - T Higuchi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - H Ozawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - K Murase
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Takatsuka
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Miyoshi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| |
Collapse
|
40
|
Higuchi T, Nishimukai A, Yanai A, Miyagawa Y, Murase K, Imamura M, Ozawa H, Takatsuka Y, Miyoshi Y. Abstract P6-16-01: Differences in patterns of change of bone turnover markers during treatment with bone-modifying agents of breast cancer patients with bone metastases. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-16-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Bone-modifying agents have demonstrated their efficacy for treatment by suppressing osteoclast function. The activity of bone-modifying agents can be monitored by means of bone resorption markers such as c-terminal crosslinking telopeptide of type I collagen (1CTP) and N-telopeptide of type I collagen (NTX) as well as bone forming marker bone-specific alkaline phosphatase (BAP). In contrast to these markers which indirectly indicate bone turnover, tartrate-resistant acid phosphatase-5b (Tracp-5b) has been established as a direct marker showing osteoclast number and activity. The aim of this study was to identify the relative significance of these bone turnover markers as indicators of treatment efficacy induced by bone-modifying agents for breast cancer patients with bone metastases.
Patients and Methods: For this study, 52 breast cancer patients with bone metastases treated with bone-modifying agents were recruited. Zoledronic acid and denosumab were administered as bone-modifying agents to 36 and 22 patients, respectively (for 6 patients, denosumab was used after zoledronic acid). Serum Tracp-5b, 1CTP, NTX and BAP were measured with, respectively, the EIA (enzyme immunoassay), RIA (two-antibody radioimmunoassay), ELISA (enzyme-linked immunosorbent assay) and CLEIA (chemiluminescent enzyme immunoassay) method. Blood samples were obtained pretreatment and 1, 3 and 6 months after treatment. Changes in these bone turnover markers were statistically analyzed with Friedman's test, and correlation between serum markers and clinicopathological factors was calculated with Mann-Whitney's test.
Results: Serum tracp-5b decreased significantly after treatment (p<0.0001). The baseline median value of Tracp-5b (457.5mU/dl, range: 173-1630mU/dl) had been reduced to 137mU/dl (91-795mU/dl) 1 month after treatment, but no further reduction was observed after that. For 13 out of 15 patients to whom Tracp-5b was administered, abnormally high levels (above 420mU/dl) decreased to normal range with one month treatment. Serum NTX was also significantly reduced after treatment (p=0.0007). The median baseline value (16.5nmolBCE/L, 6.1-52.2nmolBCE/L) was diminished after 1 month (to 10.9nmolBCE/L, 7.0-49.5nmolBCE/L), and further reduction of NTX was observed after 3 months (9.55nmolBCE/L, 6.4-56.0nmolBCE/L). Similarly, baseline BAP (15.1μg/L, 6.4-81.3μg/L) decreased significantly (p=0.0032), a reduction which was obtained after 3 months (10.15μg/L, 6.1-51.7μg/L), but not after 1 month (13.0μg/L, 7.7-137.0μg/L). On the other hand, reduction in 1CTP was not significant (p=0.83).
Conclusion and discussion: Although baseline values of the bone turnover markers Tracp-5b, NTX and BAP decreased significantly after treatment with bone-modifying agents, the pattern of reduction for these three markers varied. Tracp-5b appears to reflect efficacy of bone-modifying agents most quickly and sensitively, possibly due to its direct link to the number and activity of osteoclasts. These findings may prove usefulness of Tracp-5b when considering the efficacy of various bone-modifying agents in clinical practice.
Citation Format: Higuchi T, Nishimukai A, Yanai A, Miyagawa Y, Murase K, Imamura M, Ozawa H, Takatsuka Y, Miyoshi Y. Differences in patterns of change of bone turnover markers during treatment with bone-modifying agents of breast cancer patients with bone metastases. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-16-01.
Collapse
Affiliation(s)
- T Higuchi
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - A Nishimukai
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - A Yanai
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Miyagawa
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - K Murase
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - M Imamura
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - H Ozawa
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Takatsuka
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | - Y Miyoshi
- Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| |
Collapse
|
41
|
Yasui M, Yoneyama S, Uemura K, Kawahara T, Hattori Y, Teranishi JI, Ohta JI, Yokomizo Y, Masahiro Y, Masataka T, Uemura H, Miyoshi Y. 245P Predictive factor of metastatic castration-resistant prostate cancer patients' poor response to secondary alternative antiandrogen therapy with flutamide. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv524.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Uemura K, Miyoshi Y, Yoneyama S, Hattori Y, Teranishi J, Takebayashi S, Uemura H, Yao M. 410 Prognostic value of computer-aided diagnosis system for bone scan among men with docetaxel treatment for metastatic castration-resistance prostate cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30244-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
43
|
Yoneyama S, Miyoshi Y, Moriyama M, Uemura K, Takebayashi S, Uemura H, Yao M. 2524 Prognostic value of bone scan index (BSI) using computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31343-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Shimada K, Komiya A, Onishi K, Kise T, Miyoshi Y, Nagai Y, Kikuchi E, Nunokawa T, Sawaki T, Yokogawa N, Sugii S, Tohma S. SAT0120 Ninja, A Japanese Rheumatoid Arthritis Database, Demonstrated that the Size and Number of Swollen Joints Correlated with Increased Systemic Inflammation Markers. Digital Joint Swelling Showed Only Trace Increases of Serum C-Reactive Protein and Erythrocyte Sedimentation Rate. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
45
|
Yoneyama S, Miyoshi Y, Takebayashi S, Noguchi K. Prognostic Value of Computer-Aided Diagnosis System for Bone Scans in Hormone-Naive Prostate Cancer Patients with Bone Metastases. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Miyoshi Y, Umemoto S, Uemura H, Shibata Y, Sakamaki K, Honma S, Suzuki K, Kubota Y. High Testosterone Levels in Prostate Tissue Obtained By Needle Biopsy Correlate with Poor Prognosis Factors in Prostate Cancer Patients. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Takahashi M, Yoshioka K, Imai T, Miyoshi Y, Nakano Y, Yoshida K, Yamashita T, Furuta Y, Watanabe T, Sugiyama J, Takeda T. Degradation and synthesis of β-glucans by a Magnaporthe oryzae endotransglucosylase, a member of the glycoside hydrolase 7 family. J Biol Chem 2013; 288:13821-30. [PMID: 23530038 DOI: 10.1074/jbc.m112.448902] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Plant pathogens secrete enzymes that degrade plant cell walls to enhance infection and nutrient acquisition. RESULTS A novel endotransglucosylase catalyzes cleavage and transfer of β-glucans and decreases the physical strength of plant cell walls. CONCLUSION Endotransglucosylation causes depolymerization and polymerization of β-glucans, depending on substrate molecular size. SIGNIFICANCE Enzymatic degradation of plant cell walls is required for wall loosening, which enhances pathogen invasion. A Magnaporthe oryzae enzyme, which was encoded by the Mocel7B gene, was predicted to act on 1,3-1,4-β-glucan degradation and transglycosylation reaction of cellotriose after partial purification from a culture filtrate of M. oryzae cells, followed by liquid chromatography-tandem mass spectrometry. A recombinant MoCel7B prepared by overexpression in M. oryzae exhibited endo-typical depolymerization of polysaccharides containing β-1,4-linkages, in which 1,3-1,4-β-glucan was the best substrate. When cellooligosaccharides were used as the substrate, the recombinant enzyme generated reaction products with both shorter and longer chain lengths than the substrate. In addition, incorporation of glucose and various oligosaccharides including sulforhodamine-conjugated cellobiose, laminarioligosaccharides, gentiobiose, xylobiose, mannobiose, and xyloglucan nonasaccharide into β-1,4-linked glucans were observed after incubation with the enzyme. These results indicate that the recombinant enzyme acts as an endotransglucosylase (ETG) that cleaves the glycosidic bond of β-1,4-glucan as a donor substrate and transfers the cleaved glucan chain to another molecule functioning as an acceptor substrate. Furthermore, ETG treatment caused greater extension of heat-treated wheat coleoptiles. The result suggests that ETG functions to induce wall loosening by cleaving the 1,3-1,4-β-glucan tethers of plant cell walls. On the other hand, use of cellohexaose as a substrate for ETG resulted in the production of cellulose II with a maximum length (degree of polymerization) of 26 glucose units. Thus, ETG functions to depolymerize and polymerize β-glucans, depending on the size of the acceptor substrate.
Collapse
Affiliation(s)
- Machiko Takahashi
- Iwate Biotechnology Research Center, 22-174-4, Narita Kitakami, Iwate 024-0003, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Shibata Y, Suzuki K, Arai S, Miyoshi Y, Umemoto S, Masumori N, Kamiya N, Ichikawa T, Kitagawa Y, Mizokami A, Sugimura Y, Nonomura N, Sakai H, Honma S, Kubota Y. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy. Andrology 2013; 1:505-11. [DOI: 10.1111/j.2047-2927.2013.00068.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2012] [Revised: 01/04/2013] [Accepted: 01/07/2013] [Indexed: 11/27/2022]
Affiliation(s)
- Y. Shibata
- Department of Urology; Gunma University Graduate School of Medicine; Maebashi; Japan
| | - K. Suzuki
- Department of Urology; Gunma University Graduate School of Medicine; Maebashi; Japan
| | - S. Arai
- Department of Urology; Gunma University Graduate School of Medicine; Maebashi; Japan
| | - Y. Miyoshi
- Department of Urology; Yokohama City University Graduate School of Medicine; Yokohama; Japan
| | - S. Umemoto
- Department of Urology; Yokohama City University Graduate School of Medicine; Yokohama; Japan
| | - N. Masumori
- Department of Urologic Surgery and Andrology; Sapporo Medical University School of Medicine; Sapporo; Japan
| | - N. Kamiya
- Department of Urology; Chiba University Graduate School of Medicine; Chiba; Japan
| | - T. Ichikawa
- Department of Urology; Chiba University Graduate School of Medicine; Chiba; Japan
| | - Y. Kitagawa
- Department of Integrative Cancer Therapy and Urology; Kanazawa University Graduate School of Medical Science; Kanazawa; Japan
| | - A. Mizokami
- Department of Integrative Cancer Therapy and Urology; Kanazawa University Graduate School of Medical Science; Kanazawa; Japan
| | - Y. Sugimura
- Department of Nephro-Urologic Surgery and Andrology; Mie University Graduate School of Medicine; Tsu; Japan
| | - N. Nonomura
- Department of Urology; Osaka University Graduate School of Medicine; Osaka; Japan
| | - H. Sakai
- Department of nephro-urology; Nagasaki University Graduate School of Biomedical Sciences; Nagasaki; Japan
| | - S. Honma
- ASKA Pharma Medical Co., Ltd; Kawasaki; Japan
| | - Y. Kubota
- Department of Urology; Yokohama City University Graduate School of Medicine; Yokohama; Japan
| |
Collapse
|
49
|
Shigeoka Y, Watanabe K, Takahashi M, Hirokaga K, Takao S, Miyashita M, Wakita K, Miyoshi Y, Okuno T, Kohno S, Kishimoto M, Kokufu I. Abstract P6-07-39: Prognostic Value of Body Mass Index in Japanese Breast Cancer Patients: A Collaborative Study by the Kobe Breast Cancer Oncology Group and Hokkaido Cancer Center. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-07-39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Many recent clinical trials conducted in Western populations suggest that obesity is a prognostic factor after primary treatment in postmenopausal breast cancer patients. However, the incidence of obesity differs substantially between Asian and Western breast cancer patients. Moreover, few studies have reported the relationship between body mass index (BMI) and postsurgical prognosis in Asian breast cancer patients. A previous retrospective analysis of Japanese populations revealed that obesity might be a prognostic risk factor in Japanese breast cancer patients.
Methods: We retrospectively analyzed BMI and clinical outcomes after primary treatment in Japanese breast cancer patients of Hanshin and Hokkaido areas. We reviewed the clinical data (height, weight, BMI, estrogen receptor [ER] status, progesterone receptor status [PgR], human epidermal growth factor receptor 2 [HER2] status, and outcome) of 1,222 primary breast cancer patients with clinical stage I-III disease who were operated on between Jan 2004 and Dec 2005 at Kobe Breast Cancer Oncology Group (KBCOG) and Hokkaido Cancer Center (median follow-up period, 74 months). The patients were categorized into 4 groups: underweight (BMI, <18.5 kg/m2), normal (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), and obesity (>30.0 kg/m2). Patient characteristics, excluding age and menopausal status, were well-balanced across groups. The correlations of BMI with disease-free survival (DFS) and overall survival (OS) were analyzed using the Cox hazards model.
Results: The normal, underweight, overweight, and obesity groups contained 832 (68.1%), 92 (7.5%), 253 (20.7%), and 45 (3.7%) patients, respectively. Breast cancer recurred in 184 patients (15.0%); 75 patients died due to breast cancer recurrence, 29 died of other diseases, and 6 died of unknown causes. The univariate hazard ratio (HR) values for disease-free survival and overall survival in the overweight group were significantly lower than those in the normal group. However, there were no statistical significant differences among four groups by the multivariate analysis. We added subgroup analysis with classifications by ER and PgR status to speculate the cause for these unexpected results. Although there were no statistically significant differences, HRs for DFS and OS in the obesity group were higher than those in the normal group among ER− and/or PgR-positive patients. However, HRs for DFS and OS tended to be higher in the underweight groups and lower in the overweight groups in ER− and PgR-negative populations.
Conclusions: The incidence of obesity in the Japanese population is much lower than that in the Western population. Although results of this study were slightly different from recent findings, obesity might be a risk factor for DFS and OS in ER-positive Japanese breast cancer patients, similar to that in Western countries. In underweight patients, ER− and PgR-negative status might indicate poor prognosis. However, this study was a retrospective analysis of a limited, heterogeneous patient group. A large-scale cohort study in the Japanese population is, therefore, recommended.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-07-39.
Collapse
Affiliation(s)
- Y Shigeoka
- Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan
| | - K Watanabe
- Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan
| | - M Takahashi
- Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan
| | - K Hirokaga
- Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan
| | - S Takao
- Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan
| | - M Miyashita
- Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan
| | - K Wakita
- Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan
| | - Y Miyoshi
- Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan
| | - T Okuno
- Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan
| | - S Kohno
- Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan
| | - M Kishimoto
- Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan
| | - I Kokufu
- Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan
| |
Collapse
|
50
|
Masuda N, Sato N, Higaki K, Kashiwaba M, Matsunami N, Takano T, Yamamura J, Kaneko K, Takahashi M, Ohno S, Fujisawa T, Tsuyuki S, Miyoshi Y, Ohtani S, Yamamoto Y, Bando H, Onoda T, Kawabata H, Morita S, Ueno T, Toi M. Abstract P1-14-08: A prospective multicenter randomized phase II neo-adjuvant study of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) followed by docetaxel, cyclophosphamide and trastuzumab (TCH) versus TCH followed by FEC versus TCH alone, in patients (pts) with operable HER2 positive breast cancer: JBCRG-10 study. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-14-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The current standard treatment of primary systemic therapy (PST) in HER2 positive breast cancer is anthracyclines (A) and/or taxanes combined with trastuzumab (H) which demonstrates high pathological complete response (pCR). The pCR is considered as a predictive marker of prognosis although results are slightly different depending on the hormone receptor status. We conducted a randomized phase II study to examine sequence of treatments and necessity of A in the treatments using TCH to improve outcome and reduce cardiac toxicity in Japanese HER2 positive pts.
Methods: Pts were treated with FEC (5FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) and/or TCH (docetaxel 75 mg/m2, cyclophosphamide 600 mg/m2, H 6 mg/kg, loading by 8 mg) in 3 groups: 4 cycles of FEC followed by 4 cycles of TCH (A-TCH); 4 cycles of TCH followed by 4 cycles of FEC (TCH-A) or 6 cycles of TCH. An unplanned interim analysis was conducted due to one death by interstitial lung disease (ILD) in the A-TCH after completion of 8 cycles. The pCR results suggested A containing regimens did not exceed benefit from the current standard regimen. The study was continued by limiting allocation only to the TCH group considering efficacy and safety. The primary endpoint was pCR and secondary endpoints were overall response rate (ORR) and safety.
Results: A total of 103 pts were enrolled between Sep. 2009 and Sep. 2011; 21 pts in the A-TCH, 22 pts in the TCH-A and 60 pts in the TCH including pts enrolled after termination of random allocation. Characteristics of the 103 pts were; median age of 54 (range, 33–70), median tumor size of 35 mm (range, 12–80), 42 pts with N(+) (40.8%) and 62 ER positive pts (60.2%). Characteristics of pts in the TCH were; median age of 54.5 (range, 33–67), median tumor size of 35.5 mm (range, 12–80), 25 pts with N(+) (41.7%) and 34 ER positive pts (56.7%). No major difference was reported between groups treated with or without A. Per protocol population was 59 pts in the TCH and its pCR rate was 45.8% (95% CI, 32.2–59.3: ER negative, 61.5%; ER positive, 33.3%). ORR was 86.4% assessed by MRI or CT. Although it is an exploratory analysis, the pCR rate of A containing regimens was 39.0% (ER negative, 57.1%; ER positive, 29.6%). Adverse events ≥grade 3 were reported in 50 pts (48.5%). Reported ILD was in 5 pts (A-TCH, 1; TCH-A, 1; TCH, 3). The mean left ventricular ejection fraction (LVEF) decreased from 70.0% to 69.0% after treatment (A-TCH, 65.9%; TCH-A, 70.4%; TCH, 69.0%). Decrease of LVEF in the A-TCH was significant (p < 0.01).
Conclusion: The pCR rate of the TCH group was similar to previous reports on A including regimens. Although ILD had been occurred during the treatment containing the TCH, no other new safety issues were reported. We were not able to conclude preferable sequence of A and T since statistical power was not sufficient. However, the result of LVEF suggested TCH followed by A or TCH were preferable. Six cycles of TCH could be one of treatment options as a PST in HER2 positive breast cancer to exclude A. (UMIN000002365)
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-08.
Collapse
Affiliation(s)
- N Masuda
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - N Sato
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - K Higaki
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - M Kashiwaba
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - N Matsunami
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - T Takano
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - J Yamamura
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - K Kaneko
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - M Takahashi
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - S Ohno
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - T Fujisawa
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - S Tsuyuki
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - Y Miyoshi
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - S Ohtani
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - Y Yamamoto
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - H Bando
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - T Onoda
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - H Kawabata
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - S Morita
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - T Ueno
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| | - M Toi
- NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan
| |
Collapse
|